Details of the Drug

General Information of Drug (ID: DMLB0EZ)

Drug Name
Tamoxifen
Synonyms
tamoxifen; 10540-29-1; trans-Tamoxifen; Crisafeno; Soltamox; Tamoxifene; Diemon; Tamoxifenum; Tamoxifeno; Tamizam; Istubol; Tamoxen; Citofen; Oncomox; Valodex; Retaxim; Tamoxifene [INN-French]; Tamoxifenum [INN-Latin]; Tamoxifeno [INN-Spanish]; Tamoxifen (Z); Tamoxifen and its salts; Tamoxifen [INN:BAN]; ICI-46474; ICI 47699; TRANS FORM OF TAMOXIFEN; CCRIS 3275; UNII-094ZI81Y45; HSDB 6782; CHEMBL83; EINECS 234-118-0; 1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene; Citofen; Nourytam; Novaldex; Tamone; Tamoxifeno;Tamoxifenum; Tomaxithen; Gen-Tamoxifen; Istubal (TN); Nolvadex (TN); Nolvadex-D; Novo-Tamoxifen; Pms-Tamoxifen; Tamoplex (TN); Tamoxifen (INN); Tamoxifen (TN); Trans-Tamoxifen; Valodex (TN); TAMOXIFEN (TAMOXIFEN CITRATE (54965-24-1)); Trans-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine; (Z)-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene; (Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine; (Z)-2-(4-(1,2-diphenylbut-1-enyl)phenoxy)-N,N-dimethylethanamine; (Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine (IUPAC); (Z)-2-[4-(1,2)-DIPHENYL-1-BUTENYL)-PHENOXY]-N,N-DIMETHYLETHANAMINE; (Z)-2-[p-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine; 1-p-beta-Dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene; 1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene; 2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine; 2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine; Tamoxifen (Hormonal therapy); [3H]tamoxifen
Indication
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Approved [1]
Inflammatory breast cancer 2C62 Approved [2]
Invasive ductal breast carcinoma N.A. Approved [2]
Therapeutic Class
Anticancer Agents
Affected Organisms
Humans and other mammals
ATC Code
: Tamoxifen
L02AX: Other hormones
L02A: HORMONES AND RELATED AGENTS
L02: ENDOCRINE THERAPY
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L02BA01: Tamoxifen
L02BA: Anti-estrogens
L02B: HORMONE ANTAGONISTS AND RELATED AGENTS
L02: ENDOCRINE THERAPY
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 371.5
Logarithm of the Partition Coefficient (xlogp) 7.1
Rotatable Bond Count (rotbonds) 8
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 2
ADMET Property
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 40 mcg/L [3]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 5 h [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Clearance
The clearance of drug is 189 mL/min in postmenopausal women [5]
Elimination
Animal studies have shown 75% of radiolabelled tamoxifen recovered in the feces, with negligible collection from urine [6]
Half-life
The concentration or amount of drug in body reduced by one-half in 5 - 7 days [3]
Metabolism
The drug is metabolized via the hydroxylated to -hydroxytamoxifen [7]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.18283 micromolar/kg/day [8]
Vd
The volume of distribution (Vd) of drug is 50-60 L/kg [9]
Water Solubility
The ability of drug to dissolve in water is measured as 0.5 mg/mL [4]
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Thromboembolic event rs6025 F5 OTDMZ3LT [10]
Chemical Identifiers
Formula
C26H29NO
IUPAC Name
2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine
Canonical SMILES
CC/C(=C(\\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3
InChI
InChI=1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25-
InChIKey
NKANXQFJJICGDU-QPLCGJKRSA-N
Cross-matching ID
PubChem CID
2733526
ChEBI ID
CHEBI:41774
CAS Number
10540-29-1
UNII
094ZI81Y45
DrugBank ID
DB00675
TTD ID
D07KSG
VARIDT ID
DR00193
INTEDE ID
DR1529
ACDINA ID
D00650
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Estrogen receptor (ESR) TTZAYWL ESR1_HUMAN Antagonist [11]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Multidrug resistance-associated protein 7 (ABCC10) DTPS120 MRP7_HUMAN Substrate [12]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [13]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [14]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [15]
Cytochrome P450 2E1 (CYP2E1) DEVDYN7 CP2E1_HUMAN Substrate [16]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [17]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [18]
Cytochrome P450 1A1 (CYP1A1) DE6OQ3W CP1A1_HUMAN Substrate [19]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Substrate [20]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [21]
Cytochrome P450 2A6 (CYP2A6) DEJVYAZ CP2A6_HUMAN Substrate [16]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [22]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [23]
Cytochrome P450 2B6 (CYP2B6) DEPKLMQ CP2B6_HUMAN Substrate [24]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Substrate [25]
UDP-glucuronosyltransferase 2B7 (UGT2B7) DEB3CV1 UD2B7_HUMAN Substrate [26]
Sulfotransferase 2A1 (SULT2A1)
Main DME 		DE0P6LK ST2A1_HUMAN Substrate []
Sulfotransferase 1A1 (SULT1A1) DEYWLRK ST1A1_HUMAN Substrate [27]
UDP-glucuronosyltransferase 1A10 (UGT1A10) DEL5N6Y UD110_HUMAN Substrate [28]
Thiopurine methyltransferase (TPMT) DEFQ8VO TPMT_HUMAN Substrate [29]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Coagulation factor V (F5) OTDMZ3LT FA5_HUMAN Drug Response [10]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Breast cancer
ICD Disease Classification 2C60-2C65
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
P-glycoprotein 1 (ABCB1) DTP P-GP 7.23E-01 -8.20E-02 -3.22E-01
Multidrug resistance-associated protein 7 (ABCC10) DTP MRP7 6.29E-01 6.44E-02 9.67E-02
Breast cancer resistance protein (ABCG2) DTP BCRP 9.93E-01 -1.09E-01 -5.77E-01
Sulfotransferase 1A1 (SULT1A1) DME SULT1A1 6.22E-02 1.64E-01 5.58E-01
UDP-glucuronosyltransferase 1A1 (UGT1A1) DME UGT1A1 7.69E-01 1.91E-02 5.45E-02
Cytochrome P450 2E1 (CYP2E1) DME CYP2E1 7.75E-01 -1.76E-01 -6.23E-01
Cytochrome P450 2B6 (CYP2B6) DME CYP2B6 3.97E-02 -1.72E-01 -9.29E-01
Cytochrome P450 2A6 (CYP2A6) DME CYP2A6 7.56E-01 -6.70E-02 -3.47E-01
Cytochrome P450 1A2 (CYP1A2) DME CYP1A2 9.96E-01 -7.53E-02 -5.68E-01
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 5.82E-01 -6.00E-02 -2.69E-01
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 3.44E-01 -1.85E-01 -5.25E-01
Thiopurine methyltransferase (TPMT) DME TPMT 8.48E-01 -1.76E-01 -5.49E-01
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 7.95E-01 -7.47E-02 -2.45E-01
Cytochrome P450 1A1 (CYP1A1) DME CYP1A1 5.01E-01 -1.01E-02 -6.05E-02
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 9.09E-01 -9.26E-02 -3.68E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 9.85E-01 2.24E-02 7.33E-02
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 44 Cell Line(s) in Bone Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
RPMI-3460/CS1 GDSC1; GDSC2 3.5266 5.1257 2.5844 4.1076
ES1 GDSC1; GDSC2 3.1872 4.6045 2.5651 5.1984
EW-7 GDSC1; GDSC2 3.1969 5.6515 2.0514 8.4141
EW-1 GDSC1; GDSC2 3.2492 5.5463 2.1486 7.6424
ES6 GDSC1; GDSC2 3.32 5.9755 1.9935 8.413
EW-24 GDSC1; GDSC2 3.4839 7.2519 1.4903 11.0878
EW-22 GDSC1; GDSC2 3.6805 5.7353 2.3995 4.8772
HuO9 GDSC1; GDSC2 3.778 6.3698 2.1594 6.1345
EW-16 GDSC1; GDSC2 3.9375 6.2361 2.3405 4.6354
ES8 GDSC1; GDSC2 3.9653 6.1626 2.3954 4.2382
CHSA0108 GDSC1; GDSC2 4.1313 9.0999 1.0766 11.8368
CADO-ES1 GDSC1; GDSC2 4.1463 6.0905 2.5495 2.9493
H-EMC-SS GDSC1; GDSC2 4.2158 6.604 2.3527 3.9722
ES4 GDSC1; GDSC2 4.2987 7.4997 1.9804 6.0306
EW-18 GDSC1; GDSC2 4.3177 6.9923 2.2355 4.4636
EW-12 GDSC2 4.3215 6.2243 2.5949 2.3815
U-CH2 GDSC2 4.3594 6.5756 2.4569 3.0936
CHSA8926 GDSC1; GDSC2 4.4357 6.257 2.6457 1.9283
SK-ES-1 GDSC1; GDSC2; CTRP2 4.5112 5.6831 4.492 14.2588
ES7 GDSC1; GDSC2 4.5559 9.599 1.1429 10.4213
TC-71 GDSC1; GDSC2 4.5756 10.9523 0.4945 13.9667
Hs 822.T CTRP2 4.7073 5.5556 4.7022 12.906
EW-11 GDSC1; GDSC2 4.8095 14.022 -0.8446 19.7042
U2OS GDSC1; GDSC2; CTRP2; CTRP1 4.8689 6.4956 4.7452 12.2423
NOS-1 [Human HNSCC] GDSC1; GDSC2 4.9044 13.8578 -0.6924 18.8342
HuO-3N1 GDSC1; GDSC2 5.0308 9.7237 1.4086 7.863
CAL-72 GDSC1; GDSC2 5.054 13.357 -0.3355 16.903
EW-3 GDSC1; GDSC2 5.1752 9.3307 1.6858 6.0118
ES5 GDSC1; GDSC2 5.5192 8.3993 2.2962 2.2544
CHSA0011 GDSC1; GDSC2 5.586 9.013 2.0681 3.2873
SaOS-2 GDSC1; GDSC2; CTRP2 5.6766 11.3744 3.431 15.4046
EW-13 GDSC1; GDSC2 5.7292 7.5776 2.7151 0.4694
A-673 GDSC1; GDSC2; CTRP2 6.0344 6.6181 5.9856 4.2264
NY GDSC1; GDSC2 6.2378 8.706 2.5022 0.8107
SK-PN-DW GDSC1; GDSC2 6.5628 17.6698 -1.3637 17.8725
SK-N-MC CTRP2 7.5764 12.1974 4.6007 6.9332
SJSA-1 GDSC1; GDSC2; CTRP2 8.1698 19.4789 1.4495 17.694
TC71 CTRP2 8.1768 9.3575 6.2561 0.2006
MHH-ES-1 GDSC1; GDSC2; CTRP2 8.3894 12.7077 4.914 4.5048
G-292 clone A141B1 GDSC1; GDSC2; CTRP2 8.709 10.4758 6.0563 0.3953
SW1353 CTRP2 8.7622 10.2652 6.1544 0.2013
HOS GDSC1; GDSC2; CTRP2 8.8281 13.8843 4.6417 5.0024
CAL-78 GDSC1; GDSC2; CTRP2 8.9569 10.5112 6.1402 0.1757
MG-63 GDSC1; GDSC2; CTRP2 14.9201 31.5605 0.2206 12.3021
⏷ Show the Full List of 44 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 218 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MEC1 CTRP2 6.0849 7.0437 5.8921 4.4321
JK1 CTRP2 6.987 12.1486 4.172 9.7146
JM1 GDSC1; GDSC2; CTRP2 6.6208 10.8743 4.5094 9.002
BONNA-12 GDSC2 1.8577 13.6496 -3.1077 35.1263
LC4-1 GDSC1; GDSC2 2.1487 4.8303 1.4554 15.7303
U-698-M GDSC1; GDSC2 2.2413 4.9823 1.4799 15.2282
MHH-PREB-1 GDSC1; GDSC2 2.5497 3.495 2.4263 8.4131
SUP-B8 GDSC1; GDSC2 2.5833 6.4401 1.1114 16.2108
KMOE-2 GDSC1; GDSC2 2.5947 10.4461 -0.8629 26.0833
MHH-CALL-2 GDSC1; GDSC2 2.8088 4.2935 2.3625 7.752
ALL-PO GDSC1; GDSC2 2.8211 5.0439 2.0148 9.8564
GR-ST GDSC1; GDSC2 2.8509 9.5932 -0.2144 22.4335
MN-60 GDSC1; GDSC2 2.9161 5.3119 1.9713 9.8074
H9 GDSC1; GDSC2 2.925 25.6759 -8.1875 39.3019
Jiyoye GDSC1; GDSC2 3.0367 7.9773 0.7525 16.8143
P32/ISH GDSC1; GDSC2 3.0461 3.9754 2.7441 4.5481
Karpas-45 GDSC1; GDSC2 3.0493 4.4842 2.5005 6.0519
Loucy GDSC1; GDSC2 3.0544 5.1731 2.1649 8.1417
ARH-77 GDSC1; GDSC2 3.1242 4.4775 2.572 5.3559
BE-13 GDSC1; GDSC2 3.1744 5.6392 2.0382 8.5656
EoL-1 GDSC1; GDSC2; CTRP2 3.1807 5.9029 3.0379 23.5378
CESS GDSC1; GDSC2 3.1962 5.7416 2.0058 8.7038
IM-9 GDSC1; GDSC2 3.2419 4.4282 2.7008 4.1715
BC-1 GDSC1; GDSC2 3.2589 8.3288 0.7658 16.0538
MOLT-13 GDSC1; GDSC2 3.2596 7.7548 1.0533 14.3842
RPMI-8866 GDSC1 3.2748 19.7278 -5.6002 34.3744
DG-75 GDSC1; GDSC2 3.2924 6.4222 1.7471 10.0434
JSC-1 GDSC2 3.3245 6.7743 1.5979 10.8805
DND-41 GDSC1; GDSC2; CTRP2 3.3366 5.316 3.2919 22.1625
KMS-21-BM CTRP2 3.3679 4.6068 3.3645 21.815
HC-1 GDSC1; GDSC2 3.3965 6.3816 1.8538 9.0726
Sc-1 GDSC1 3.4208 5.5383 1.511 3.3412
WSU-NHL GDSC1; GDSC2 3.4285 7.6825 1.2298 12.8334
OCI-AML-3 GDSC1; GDSC2; CTRP2; CTRP1 3.4366 5.0447 3.4185 21.407
GDM-1 GDSC1; GDSC2; CTRP1 3.4433 5.1514 3.4157 23.7359
KMS-12-BM GDSC2; CTRP2 3.4548 4.9847 3.4407 21.2727
ATN-1 GDSC1; GDSC2 3.4571 5.8393 2.174 6.8838
KY821 GDSC1; GDSC2 3.4603 4.5048 2.8415 2.6627
RC-K8 GDSC1; GDSC2 3.4681 8.0166 1.0953 13.5221
YT GDSC1; GDSC2 3.4721 5.831 2.1902 6.7398
EB2 GDSC1; GDSC2 3.5441 6.264 2.0318 7.5418
HAL-01 GDSC1; GDSC2 3.5452 9.3632 0.4853 16.7609
CTV-1 GDSC1; GDSC2 3.5518 4.7725 2.7782 2.8291
VAL GDSC1; GDSC2 3.5761 6.5762 1.9015 8.2734
ML-2 GDSC1; GDSC2 3.5991 6.3936 2.0105 7.5276
Farage GDSC1; GDSC2 3.6014 8.9844 0.7201 15.3063
AML-193 CTRP2 3.6356 4.5128 3.6352 20.0235
DoHH2 GDSC2 3.638 5.0692 2.6956 3.1355
WIL2 NS GDSC1; GDSC2 3.6756 5.7493 2.3889 4.9551
SCC-3 GDSC2 3.6847 5.3891 2.5729 3.786
MLMA GDSC1; GDSC2 3.6864 9.6945 0.4341 16.6313
WSU-DLCL2 GDSC1; GDSC2; CTRP2; CTRP1 3.7327 4.4896 3.7326 19.3762
ME1 GDSC1; GDSC2 3.7474 6.2992 2.1713 6.1364
P30/OHK GDSC1; GDSC2 3.7732 5.1279 2.7617 2.4295
Raji GDSC1; GDSC2 3.7991 5.6832 2.5114 3.8993
Karpas-231 GDSC1; GDSC2 3.8081 5.3259 2.6904 2.7865
KHM-1B CTRP2 3.8125 5.1131 3.8027 18.8776
JVM-3 GDSC1; GDSC2; CTRP2 3.8133 6.0916 3.6861 19.2756
L-428 GDSC1; GDSC2; CTRP2 3.8505 5.6804 3.7942 18.7823
MEG-01 GDSC1; GDSC2 3.8713 6.0186 2.3995 4.4236
CML-T1 GDSC1; GDSC2; CTRP2 3.873 5.9762 3.7726 18.7849
RPMI-8226 GDSC1; GDSC2; CTRP2; CTRP1 3.8834 5.0572 3.8774 18.3929
KMS-20 CTRP2 3.888 4.8315 3.8866 18.3469
PL21 CTRP2; CTRP1 3.8977 5.3268 3.8789 18.3408
OCI-AML-2 GDSC1; GDSC2 3.9238 6.2491 2.3245 4.7646
Karpas-299 GDSC1; GDSC2 4.0029 8.4953 1.2785 10.9758
SUP-T11 CTRP2 4.0195 5.5978 3.9832 17.5892
Reh GDSC1; GDSC2 4.0278 7.5213 1.7775 7.8883
NK-92MI GDSC2 4.0464 7.4009 1.8502 7.3977
VL51 GDSC1; GDSC2 4.0666 6.9238 2.0975 5.8331
NOMO-1 GDSC1; GDSC2; CTRP1 4.0696 5.3915 4.0509 18.9596
THP-1 GDSC1; GDSC2; CTRP2; CTRP1 4.1236 5.4038 4.1083 16.8254
TALL-1 [Human adult T-ALL] GDSC2; CTRP2 4.1298 6.4131 3.9595 17.3227
NKM-1 GDSC1; GDSC2 4.1374 7.0636 2.0794 5.7849
ALL-SIL GDSC1; GDSC2 4.1646 6.7572 2.2457 4.7173
NB4 GDSC1; GDSC2 4.215 6.4551 2.4224 3.5617
LP-1 GDSC1; GDSC2; CTRP2; CTRP1 4.2161 5.5024 4.1978 16.2199
Ku812 GDSC1; GDSC2; CTRP2 4.2166 7.2779 3.7982 17.6507
SU-DHL-5 GDSC1; GDSC2; CTRP1 4.22 4.8788 4.2198 17.7507
DEL GDSC1; GDSC2; CTRP2 4.2315 4.7333 4.2315 16.0561
BALL-1 GDSC1; GDSC2 4.2419 6.4272 2.4526 3.3336
SKM-1 GDSC1; GDSC2; CTRP2; CTRP1 4.2635 5.6957 4.2305 15.954
KE-37 GDSC1; GDSC2; CTRP2 4.3244 5.3221 4.319 15.4558
JVM-2 GDSC1; GDSC2 4.3612 9.1701 1.2123 10.4787
KMS-28BM CTRP2 4.3663 5.91 4.3134 15.3379
CRO-AP2 GDSC1; GDSC2 4.4021 6.2674 2.6222 2.104
TUR GDSC1; GDSC2 4.4118 6.7218 2.4216 3.2019
Ramos.2G6.4C10 GDSC1; GDSC2 4.4288 16.2918 -2.2652 25.7283
EJM GDSC1; GDSC2; CTRP2; CTRP1 4.4574 5.455 4.4501 14.5766
HuT 78 CTRP2 4.4789 6.0494 4.4129 14.6342
CTB-1 GDSC1; GDSC2 4.52 7.6143 2.0732 5.0208
Pfeiffer CTRP2 4.5565 6.8939 4.293 14.8237
KG-1 GDSC1; GDSC2 4.6249 7.3598 2.2579 3.7568
NALM-6 GDSC1; GDSC2; CTRP2 4.6269 8.9468 3.5642 17.4156
KMS-26 CTRP2 4.644 5.5146 4.6389 13.3276
QIMR-WIL GDSC1; GDSC2 4.6511 8.2644 1.8513 6.0645
P12-Ichikawa GDSC1; GDSC2; CTRP2 4.6851 6.7428 4.4784 13.7624
HH [Human lymphoma] GDSC1; GDSC2; CTRP2 4.7139 7.6233 4.2077 14.6893
KOPN-8 GDSC1; GDSC2 4.7153 10.4014 0.8655 11.6187
RS4;11 GDSC1; GDSC2; CTRP2 4.7236 8.1486 4.0071 15.4346
NU-DHL-1 CTRP2 4.8125 5.6453 4.8065 12.2093
TK [Human B-cell lymphoma] GDSC1; GDSC2 4.8401 6.3862 2.7946 0.7726
EM-2 GDSC1; GDSC2; CTRP2 4.8641 6.1198 4.8155 12.0107
MOLM-13 GDSC1; GDSC2; CTRP2 4.8872 6.0019 4.8564 11.7957
MOLT-4 GDSC1; GDSC2 4.9128 13.1414 -0.3333 17.229
Mono-Mac-1 CTRP2 4.924 7.3836 4.5233 12.8988
SU-DHL-16 GDSC1; GDSC2 4.936 10.5492 0.9489 10.6557
SU-DHL-4 GDSC1; GDSC2; CTRP2; CTRP1 4.9399 5.944 4.9185 11.4132
MY-M12 GDSC2 4.9571 7.862 2.2263 3.3796
KMS-34 CTRP2 4.9695 7.8989 4.3684 13.3676
GA-10 GDSC1; GDSC2; CTRP2 4.974 7.3914 4.5741 12.5651
EB1 CTRP2 4.9807 7.4555 4.557 12.6114
JURL-MK1 GDSC1; CTRP2 4.9899 6.729 4.8149 11.6226
ROS-50 GDSC1; GDSC2 5.0175 7.5772 2.3859 2.4508
L-1236 GDSC1; GDSC2 5.0863 10.8734 0.8962 10.6172
Daudi GDSC1; GDSC2 5.1004 6.8988 2.7093 0.8855
M-07e CTRP2 5.1023 8.5114 4.2425 13.511
KMS-27 CTRP2 5.1209 5.753 5.1181 10.1457
PL-21 GDSC1; GDSC2 5.1567 11.4432 0.67 11.6861
F-36P CTRP2 5.1882 9.3217 3.9585 14.4287
CCRF-CEM GDSC1; GDSC2 5.2203 13.1987 -0.1377 15.6003
KMS-11 GDSC1; GDSC2; CTRP2; CTRP1 5.2296 8.7345 4.2708 13.0742
MOLM-16 GDSC1; GDSC2; CTRP2; CTRP1 5.2564 10.5929 3.4204 16.4141
MV4-11 GDSC1; GDSC2; CTRP2 5.2687 9.1302 4.1273 13.5524
KMS-18 CTRP2 5.2934 8.5322 4.4269 12.2885
OCI-Ly7 GDSC1; GDSC2 5.3491 6.6242 2.9109 0.1744
BC-3 GDSC2 5.4501 6.9795 2.8233 0.3209
697 GDSC1; GDSC2; CTRP2 5.5453 7.8023 5.0085 9.3287
Karpas-1106P GDSC1; GDSC2 5.5917 13.7543 -0.1452 14.8062
HDLM-2 GDSC1; GDSC2; CTRP2 5.6083 10.7131 3.6927 14.5081
DB GDSC1; GDSC2; CTRP2 5.6315 7.9443 5.0339 9.0053
U-937 CTRP2; CTRP1 5.637 12.0102 3.0814 16.8684
Hs 445 GDSC1; GDSC2 5.6528 7.0213 2.8829 0.1463
Kasumi-2 CTRP2 5.7047 10.7461 3.7657 13.9952
SUP-M2 GDSC1; GDSC2; CTRP2 5.7103 9.1971 4.525 10.8765
BL-70 CTRP2; CTRP1 5.7516 8.1408 5.065 8.5785
MOLT-3 CTRP2 5.8181 7.5197 5.4124 7.0208
OPM-2 GDSC1; GDSC2; CTRP2 5.8439 9.1421 4.6784 9.937
HPB-ALL CTRP2 5.8536 8.2428 5.118 8.114
KYO-1 CTRP2 5.903 7.2389 5.6206 5.979
SET-2 CTRP2 5.929 6.5777 5.8807 4.9251
KO52 CTRP2 5.9824 6.5801 5.9383 4.5552
HD-MY-Z CTRP2 5.9966 6.6741 5.929 4.5454
CA46 GDSC1; GDSC2; CTRP2 6.0684 9.2225 4.8483 8.728
SK-MM-2 GDSC1; GDSC2; CTRP2 6.1111 8.3658 5.3067 6.7343
MOTN-1 CTRP2 6.1918 9.2436 4.9504 8.0334
A3/Kawakami GDSC1; GDSC2; CTRP2 6.2799 6.9845 6.1208 3.017
Namalwa GDSC1; GDSC2; CTRP2 6.2991 9.573 4.8829 8.0872
OCI-M1 GDSC1; GDSC2; CTRP2 6.3069 6.8618 6.2001 2.6356
ST486 GDSC1; GDSC2; CTRP2 6.3305 9.8541 4.7707 8.4907
MC116 GDSC1; GDSC2; CTRP2 6.3835 14.932 2.2809 18.2539
Peer CTRP2 6.4202 10.6261 4.4634 9.5915
MOLP-2 CTRP2 6.7766 9.4977 5.326 5.2833
MOLP-8 GDSC1; GDSC2; CTRP2 6.8226 9.4395 5.392 4.9223
SIG-M5 GDSC2; CTRP2 6.8574 7.9531 6.1575 1.6656
TF-1 CTRP2 6.905 9.4773 5.4385 4.5801
SU-DHL-1 GDSC2; CTRP2 6.9094 10.1874 5.0883 6.0376
Ri-1 CTRP2 7.023 15.0839 2.7355 15.3319
SU-DHL-6 GDSC1; GDSC2; CTRP2 7.0768 16.1487 2.2473 17.0018
PF-382 GDSC1; GDSC2; CTRP2 7.1864 10.8483 4.9748 6.0288
U266B1 GDSC1; GDSC2; CTRP2 7.2121 11.7366 4.5542 7.7319
BL-41 GDSC1; GDSC2; CTRP2 7.2383 12.5764 4.1573 9.3244
Ci-1 CTRP2 7.2704 8.1 6.3478 0.4377
MOLT-16 GDSC1; GDSC2; CTRP2 7.3918 12.2799 4.4223 7.9704
K-562 GDSC1; GDSC2; CTRP2 7.421 11.5418 4.8086 6.329
HL-60 GDSC1; GDSC2; CTRP2 7.4929 12.1283 4.5731 7.182
RCH-ACV GDSC1; GDSC2; CTRP2 7.5125 10.2314 5.5122 3.3153
SU-DHL-10 GDSC1; GDSC2; CTRP2 7.5347 9.032 6.0851 1.086
A4/Fukuda GDSC1; GDSC2; CTRP2 7.5734 10.2546 5.542 3.1116
REC-1 CTRP2 7.7523 11.6545 4.9913 5.0697
OCI-Ly3 CTRP2 7.8171 10.6325 5.5219 2.8711
RL GDSC1; GDSC2; CTRP2 7.8813 11.3978 5.2022 4.0421
OCI-Ly19 GDSC1; GDSC2; CTRP2 8.0181 11.3083 5.3333 3.3491
SUP-T1 GDSC1; GDSC2; CTRP2 8.0191 14.3916 3.8477 9.2735
OCI-Ly10 CTRP2; CTRP1 8.0261 14.2341 3.93 8.9352
NCO2 CTRP2 8.1407 11.4685 5.3356 3.1892
JJN-3 GDSC1; GDSC2; CTRP2 8.1587 13.3984 4.4305 6.7323
P31/FUJ GDSC1; GDSC2; CTRP2 8.1699 12.8231 4.7149 5.5817
Mino CTRP2 8.1905 18.2924 2.053 15.6727
Karpas-422 GDSC1; GDSC2; CTRP2 8.2014 11.4268 5.3921 2.9037
KE-97 CTRP2 8.2082 11.4584 5.3817 2.9347
MHH-CALL-4 GDSC2; CTRP2 8.2709 10.9694 5.6393 1.9271
ME1 CTRP2 8.2736 10.1808 5.9782 0.8223
CMK GDSC1; CTRP2 8.2755 9.4733 6.2525 0.1775
HEL 92.1.7 CTRP2 8.3071 13.402 4.5303 6.1229
HT GDSC1; GDSC2; CTRP2 8.325 9.7659 6.1645 0.3238
MOLM-6 CTRP2 8.3584 18.6515 2.0022 15.5621
NU-DUL-1 GDSC1; GDSC2; CTRP2; CTRP1 8.3788 12.5536 4.9794 4.2647
Mono-Mac-6 GDSC1; GDSC2; CTRP2 8.443 16.0668 3.3346 10.6074
EHEB GDSC1; CTRP2 8.4584 16.438 3.1644 11.2292
Granta-519 GDSC1; GDSC2; CTRP2 8.4613 11.7979 5.3776 2.6684
RPMI-8402 GDSC1; GDSC2; CTRP2 8.4882 13.6788 4.5192 5.9169
OCI-AML-5 GDSC1; CTRP2 8.5003 9.4646 6.3365 0.0422
JeKo-1 GDSC1; GDSC2; CTRP2 8.5264 14.7401 4.0369 7.758
Karpas-620 GDSC1; GDSC2; CTRP2 8.5307 17.9366 2.4824 13.6133
HEL GDSC1; GDSC2; CTRP2 8.5966 9.7546 6.2721 0.0852
Ki-JK CTRP2 8.6067 13.4981 4.6819 5.1266
NCI-H929 GDSC1; GDSC2; CTRP2 8.7639 10.1215 6.2057 0.1309
SUP-B15 GDSC2; CTRP2 8.831 13.4904 4.8261 4.2995
SUP-HD1 GDSC1; GDSC2; CTRP2 8.8317 13.8485 4.6606 4.9259
RPMI-6666 GDSC1; GDSC2; CTRP2 8.8778 10.3822 6.1563 0.1712
LAMA-84 GDSC1; GDSC2; CTRP2 8.8913 10.545 6.1034 0.2467
Jurkat GDSC1; GDSC2; CTRP2 8.8953 10.2894 6.195 0.1197
KM-H2 GDSC1; GDSC2; CTRP2 8.9078 10.3617 6.1745 0.1416
Kasumi-1 GDSC1; GDSC2; CTRP2 8.9205 10.7728 6.0317 0.3648
Hs 611.T CTRP2 8.9404 17.2715 3.1009 10.7291
P3HR-1 CTRP2 8.9409 16.0026 3.7127 8.4234
KCL-22 GDSC1; GDSC2; CTRP2 9.019 10.7663 6.0728 0.2605
KMM-1 CTRP2 9.3372 11.5683 5.9048 0.4604
Toledo CTRP2 9.3883 20.7256 1.7385 14.7916
SU-DHL-8 GDSC1; GDSC2; CTRP2 9.9317 18.6315 3.1187 9.2769
BV-173 GDSC1; GDSC2; CTRP2 10.1292 19.3381 2.9133 9.7469
L-540 GDSC1; GDSC2; CTRP2 10.2831 17.9023 3.6809 6.8225
MHH-CALL-3 CTRP2 10.368 19.0061 3.2221 8.3539
MM1.S GDSC2; CTRP2 10.5332 20.8649 2.4548 10.7975
SR GDSC1; GDSC2; CTRP2 11.5602 22.5117 2.3369 9.9125
L-363 GDSC1; GDSC2; CTRP2 12.5837 25.5346 1.5702 11.1041
AMO1 GDSC1; GDSC2; CTRP2; CTRP1 13.1419 27.2987 1.0985 11.8427
⏷ Show the Full List of 218 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 28 Cell Line(s) in Oesophagus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TE8 CTRP2 4.0631 10.2947 2.3881 23.3291
TE15 CTRP2 6.645 8.5059 5.7138 3.9031
T.T GDSC1; GDSC2 2.7224 3.9031 2.4515 7.545
TE-15 GDSC1 4.1319 8.0905 0.7702 6.9296
KYSE-270 GDSC1; GDSC2 4.1676 7.0006 2.1308 5.4058
TE-6 GDSC1; GDSC2; CTRP2 4.1891 6.868 3.9005 17.3549
TE-8 GDSC1; GDSC2 4.2345 6.9454 2.2027 4.8295
KYSE-410 GDSC1; GDSC2; CTRP2 4.2662 6.5118 4.0839 16.4585
KYSE-30 CTRP2 4.7193 5.6542 4.7102 12.8397
KYSE-510 GDSC1; GDSC2; CTRP2 4.9527 5.9276 4.9335 11.3204
KYSE-520 GDSC1; GDSC2; CTRP2 5.1449 6.9197 4.9252 10.7574
TE-4 GDSC1; GDSC2; CTRP2 5.4689 11.6047 3.1271 17.0717
TE-5 GDSC1; GDSC2; CTRP2 6.0683 6.7729 5.9763 4.1589
TE-14 CTRP2 7.0206 14.1751 3.1874 13.6137
OE33 GDSC1; GDSC2; CTRP2 8.177 11.9695 5.1246 3.9574
OE21 GDSC1; GDSC2; CTRP2 8.2666 18.2667 2.1232 15.3038
OE19 GDSC1; GDSC2; CTRP2 8.3276 11.4176 5.4713 2.4701
KYSE-450 GDSC1; GDSC2; CTRP2 8.5376 14.1621 4.3218 6.6242
KYSE-180 GDSC1; GDSC2; CTRP2 8.7308 15.9128 3.6123 9.1093
TE-9 GDSC1; GDSC2; CTRP2 8.9017 10.1922 6.2305 0.0828
COLO 680N GDSC1; GDSC2; CTRP2 8.9664 12.4399 5.3759 2.1791
TE-11 GDSC1; GDSC2; CTRP2 9.1112 13.9869 4.7679 4.1942
TE-10 GDSC1; GDSC2; CTRP2 9.3759 10.9921 6.1251 0.1179
KYSE-70 GDSC1; GDSC2; CTRP2 9.4183 11.0919 6.106 0.131
TE-1 GDSC1; GDSC2; CTRP2 9.5046 17.3038 3.468 8.571
EC-GI-10 GDSC1; GDSC2; CTRP2 9.9419 18.6981 3.0939 9.3524
KYSE-140 GDSC2; CTRP2 10.0588 24.2439 0.502 17.5031
KYSE-150 GDSC1; GDSC2; CTRP2 10.6399 17.2853 4.1687 4.7233
⏷ Show the Full List of 28 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 40 Cell Line(s) in Pancreas Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
N2a-PK1 CTRP2 8.9447 10.7686 6.0429 0.3351
KP-1N GDSC1; GDSC2 3.9187 5.9019 2.4891 3.77
PL4 GDSC1; GDSC2 4.1451 6.4924 2.3591 4.0771
Panc 10.05 GDSC1; GDSC2; CTRP2 4.5392 7.0308 3.9014 10.466
SU.86.86 GDSC1; GDSC2; CTRP2 4.741 5.8838 4.7149 12.7529
KP-4 GDSC1; GDSC2; CTRP2 4.8697 5.8885 4.8499 11.8748
Capan-2 GDSC1; GDSC2; CTRP2 4.8743 7.7298 4.3366 13.7507
SNU-410 CTRP2 5.8106 7.1378 5.5643 6.4488
MIA PaCa-2 GDSC2; CTRP2 5.9982 6.5738 5.957 4.4396
Panc 08.13 GDSC1; GDSC2; CTRP2 6.0085 10.0423 4.3899 10.761
PaTu 8988s CTRP2 6.0779 6.6201 6.0326 3.9245
Capan-1 GDSC1; GDSC2; CTRP2 6.1561 6.8145 6.0568 3.604
Panc 04.03 GDSC1; GDSC2; CTRP2 6.1997 6.7913 6.1122 3.2709
Panc 03.27 GDSC1; GDSC2; CTRP2 6.2215 6.7609 6.1464 3.0803
PSN1 GDSC1; GDSC2; CTRP2 6.4288 7.3391 6.104 2.7189
MZ-PC-1 GDSC1; GDSC2 6.7612 9.1843 2.5334 0.4787
Hs 766T GDSC1; GDSC2; CTRP2 6.8681 10.7728 4.7632 7.4733
SNU-213 CTRP2 7.7954 9.5478 6.0021 1.1248
PaTu 8902 GDSC1; GDSC2; CTRP2; CTRP1 8.0891 9.3672 6.2169 0.3101
HPAF-II GDSC1; GDSC2; CTRP2 8.2408 12.7651 4.7899 5.1864
PaTu 8988t GDSC1; GDSC2; CTRP2 8.289 9.5946 6.2137 0.2406
HuP-T3 GDSC1; GDSC2; CTRP2 8.3674 11.4636 5.4737 2.4194
SUIT-2 GDSC1; GDSC2; CTRP2 8.3776 9.7766 6.1819 0.2696
SW1990 GDSC1; GDSC2; CTRP2 8.3942 12.8548 4.8478 4.7558
L3.3 CTRP2 8.4476 9.7089 6.2337 0.1615
DAN-G GDSC1; GDSC2; CTRP2 8.5393 10.3306 6.0398 0.5062
YAPC GDSC1; GDSC2; CTRP2 8.5861 9.8726 6.2275 0.1388
Panc 05.04 CTRP2 8.6537 10.153 6.1532 0.2327
PK-45H CTRP2 8.6757 13.0554 4.9316 4.0848
HPAC GDSC1; GDSC2; CTRP2 8.6765 15.5052 3.7715 8.5747
Panc 02.03 GDSC1; GDSC2; CTRP2 8.7004 10.3504 6.0994 0.3132
PK-59 CTRP2 8.778 13.5506 4.7655 4.592
QGP-1 GDSC1; GDSC2; CTRP2 8.8018 10.6926 6.013 0.4485
TCC-Pan2 CTRP2 8.8465 10.4719 6.1125 0.2445
KP-2 GDSC1; GDSC2; CTRP2 9.0898 12.0635 5.599 1.3688
BxPC-3 GDSC1; GDSC2; CTRP2 9.152 11.138 5.9896 0.3639
HuP-T4 GDSC1; GDSC2; CTRP2 9.2265 15.2155 4.2716 5.9158
KP-3 GDSC1; GDSC2; CTRP2 9.3137 11.5344 5.9079 0.4629
AsPC-1 GDSC1; GDSC2; CTRP2 10.7391 18.9455 3.4781 7.0164
CFPAC-1 GDSC1; GDSC2; CTRP2 12.3187 26.7078 0.8552 13.4867
⏷ Show the Full List of 40 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 75 Cell Line(s) in Skin Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SH4 CTRP2 12.8156 39.7749 -5.1022 25.2637
WM35 GDSC1; GDSC2 3.0209 4.2843 2.5715 5.7055
M14 GDSC1; GDSC2 3.4296 6.2697 1.9368 8.4562
HMV-II GDSC1; GDSC2 3.6903 7.6053 1.479 10.5868
GAK GDSC1; GDSC2 3.8012 6.0355 2.3409 4.9488
WM278 GDSC1; GDSC2 3.951 7.763 1.6014 9.157
Hs 940.T GDSC1; GDSC2; CTRP2 4.0386 4.8693 4.0378 17.3424
IGR-37 GDSC1; GDSC2; CTRP2 4.1342 5.1309 4.1307 16.7152
Hs 934.T CTRP2 4.1644 4.6921 4.1644 16.5025
MZ-MEL-7 GDSC1; GDSC2 4.1694 5.9708 2.6195 2.5034
CHL-1 GDSC1; GDSC2 4.29 6.9419 2.2412 4.4852
SK-MEL-1 GDSC1; GDSC2; CTRP2; CTRP1 4.4041 5.3772 4.3985 14.926
SK-MEL-28 GDSC1; GDSC2; CTRP2; CTRP1 4.6097 5.4576 4.6058 13.5517
A-388 GDSC1; GDSC2 4.7503 6.7414 2.6046 1.7092
RPMI-7951 GDSC1; GDSC2; CTRP2 4.7767 5.6773 4.7682 12.4558
LB373-MEL-D GDSC1; GDSC2 4.7823 5.9785 2.9263 0.3613
A-375 GDSC1; GDSC2; CTRP2; CTRP1 4.7828 5.8565 4.7615 12.4584
LB2518-MEL GDSC1; GDSC2 4.822 6.1761 2.8683 0.5198
Hs 688(A).T CTRP2 4.8263 5.8312 4.8095 12.1535
SH-4 GDSC1; GDSC2 4.8354 9.8796 1.2026 9.4495
A-431 GDSC1; GDSC2 4.8551 7.0796 2.5146 2.0195
CP66-MEL GDSC1; GDSC2 4.9576 6.0454 2.9697 0.1793
DJM-1 GDSC2 5.1221 7.498 2.4747 1.8802
IST-MEL1 GDSC1; GDSC2 5.1548 7.2545 2.5918 1.3144
SK-MEL-24 GDSC1; GDSC2; CTRP2 5.2417 7.5739 4.7877 11.0033
Hs 938.T GDSC1; GDSC2 5.2831 6.8742 2.7963 0.4688
MMAc-SF GDSC1; GDSC2 5.3992 7.1462 2.7422 0.5647
MZ-MEL-2 GDSC1; GDSC2 5.4578 7.7247 2.5437 1.2302
CP50-MEL-B GDSC1; GDSC2 5.4793 7.0583 2.8062 0.3497
G-mel GDSC1; GDSC2 5.5278 7.0081 2.8423 0.2511
COLO 679 GDSC1; GDSC2 5.5802 7.0516 2.8464 0.2267
VMRC-MELG GDSC1; GDSC2 5.702 7.0487 2.8908 0.1254
451Lu GDSC1; GDSC2 5.7026 7.2596 2.8186 0.2429
COLO 783 GDSC1; GDSC2 5.7775 7.1385 2.8867 0.1169
WM1552C GDSC1; GDSC2 5.8104 7.7119 2.698 0.4764
HT-144 GDSC1; GDSC2; CTRP2 5.9007 6.8118 5.7815 5.3714
WM115 GDSC1; GDSC2; CTRP2 5.921 6.4734 5.8941 4.9029
WM983B CTRP2 5.924 9.5365 4.5612 10.2388
UACC-257 GDSC1; GDSC2; CTRP2 5.9638 11.6104 3.5733 14.2042
MeWo GDSC1; GDSC2; CTRP2 6.0132 6.5611 5.9763 4.3249
WT2-iPS GDSC1; GDSC2; CTRP2 6.0369 6.5894 5.9955 4.183
RVH-421 GDSC1; GDSC2; CTRP2 6.1 6.5553 6.0719 3.7166
Hs 895.T CTRP2 6.1544 6.6267 6.1143 3.3974
WM266-4 CTRP2 6.1556 6.5991 6.1225 3.3642
UACC-62 GDSC1; GDSC2; CTRP2 6.1673 6.4931 6.1559 3.2104
WM88 CTRP2 6.2027 6.7081 6.1435 3.146
Hs 294T CTRP2 6.21 6.662 6.1652 3.0448
SK-MEL-2 GDSC1; GDSC2; CTRP2 7.3244 12.3494 4.3365 8.4381
Hs 839.T CTRP2 7.9524 8.895 6.3365 0.1321
SK-MEL-30 GDSC1; GDSC2; CTRP2 8.0412 9.3181 6.2154 0.3344
CJM [Human melanoma] CTRP2 8.0694 9.4127 6.1911 0.3771
Hs 936.T CTRP2 8.1147 10.3051 5.8449 1.3666
IPC-298 GDSC1; GDSC2; CTRP2 8.1861 9.6383 6.1545 0.407
SK-MEL-3 GDSC1; GDSC2; CTRP2 8.2164 10.9546 5.6151 2.0676
SK-MEL-31 GDSC1; GDSC2; CTRP2 8.231 9.9381 6.0565 0.6304
A2058 GDSC1; GDSC2; CTRP2 8.2857 9.4941 6.2489 0.1804
IGR-1 GDSC1; GDSC2; CTRP2 8.2877 10.1805 5.9851 0.7932
LOX-IMVI GDSC1; GDSC2; CTRP2 8.3114 10.0313 6.0561 0.5848
WM793 GDSC1; GDSC2; CTRP2 8.3714 9.6766 6.2161 0.2101
WM1799 CTRP2 8.3747 9.7548 6.1888 0.2577
SK-MEL-5 GDSC1; GDSC2; CTRP2; CTRP1 8.4022 10.3332 5.9772 0.7419
HMCB CTRP2 8.4799 9.3869 6.3553 0.032
K029AX CTRP2 8.579 10.0031 6.1784 0.2126
Mel Ho GDSC1; GDSC2; CTRP2 8.6027 10.1671 6.128 0.2933
MDA-MB-435S CTRP2 8.6425 9.9239 6.2302 0.1241
A101D GDSC1; GDSC2; CTRP2 8.6669 10.9702 5.8438 0.9458
Hs 852.T CTRP2; CTRP1 8.7569 10.419 6.0967 0.2991
IGR-39 CTRP2 8.7982 9.9527 6.2753 0.0575
COLO 792 GDSC1; GDSC2; CTRP2 8.8259 10.7207 6.0124 0.4398
COLO 829 GDSC1; GDSC2; CTRP2 8.8384 12.9854 5.0615 3.4159
COLO 800 GDSC1; GDSC2; CTRP2 8.9927 10.7409 6.0718 0.2696
G-361 GDSC1; GDSC2; CTRP2 9.0446 10.5667 6.153 0.1419
Hs 944.T CTRP2 9.7306 17.0173 3.7485 7.2422
Mel JuSo GDSC1; GDSC2; CTRP2 10.6427 18.7668 3.5019 7.0425
EquiPSC Line K2 GDSC1; GDSC2 6.2862 8.2092 2.7006 0.2921
⏷ Show the Full List of 75 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 11 Cell Line(s) in Aero Dig Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
OACM5.1 C GDSC1; GDSC2 3.2251 6.2107 1.7961 9.9365
KYSE-220 GDSC1; GDSC2 3.3448 4.6175 2.6931 3.9153
KYSE-50 GDSC1; GDSC2 3.75 5.6619 2.4867 4.166
SK-GT-4 GDSC1; GDSC2 4.1276 10.1197 0.5689 14.7022
OACP4 C GDSC1; GDSC2 4.1748 7.0318 2.1207 5.4512
FLO-1 GDSC1; GDSC2 4.5751 11.7659 0.0934 16.0254
KYAE-1 GDSC1; GDSC2 4.7091 9.372 1.3604 8.8179
ESO-26 GDSC1; GDSC2 4.7379 7.8935 2.0808 4.5646
ESO-51 GDSC1; GDSC2 5.0415 7.0235 2.632 1.2544
HCE-4 GDSC1; GDSC2 5.5241 13.6803 -0.1566 15.0069
TE-12 GDSC1; GDSC2 5.6557 8.6118 2.2756 2.1926
⏷ Show the Full List of 11 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Ascites Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
COLO 684 GDSC1; GDSC2; CTRP2 5.8349 13.058 2.74 17.7354
Cancer Drug Sensitivity Data Curated from 35 Cell Line(s) in Autonomic Ganglia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SJNB-13 GDSC1; GDSC2 2.9359 3.5775 2.8111 4.5667
SJNB-14 GDSC1; GDSC2 3.2254 5.5466 2.1281 7.8429
SJNB-12 GDSC1; GDSC2 3.3161 7.5173 1.2194 13.2245
NB(TU)1 GDSC1; GDSC2 3.6136 5.1747 2.626 3.6277
CHP-134 GDSC2 3.7779 5.3473 2.6594 3.0398
SiMa GDSC1; GDSC2 3.8303 6.3524 2.2067 5.7125
GOTO GDSC1; GDSC2 3.8415 6.3445 2.2187 5.6106
TGW GDSC1; GDSC2 3.8558 6.4151 2.1946 5.726
IMR-32 CTRP2 4.1147 12.4953 1.4132 26.4419
SJNB-6 GDSC1; GDSC2 4.1483 6.4742 2.3699 4.0059
SK-N-DZ GDSC1; GDSC2; CTRP2 4.1669 10.6934 2.3097 23.3301
SK-N-BE(2) CTRP2 4.212 4.9692 4.2114 16.1876
KP-N-YS GDSC2 4.3876 6.7545 2.3916 3.4174
SJNB-10 GDSC1; GDSC2 4.4694 10.467 0.6547 13.3666
NH-12 GDSC1; GDSC2 4.5873 6.5943 2.5811 2.0471
SK-N-MC-IXC GDSC1; GDSC2 4.7181 5.6525 3.0192 0.1572
SK-N-BE(2)-M17 GDSC1; GDSC2 4.7207 7.0351 2.4607 2.485
NB69 GDSC2 4.7427 24.7146 -6.2146 33.4483
LA-N-6 GDSC1; GDSC2 4.7592 6.5379 2.695 1.2712
KP-N-RT-BM-1 GDSC2 4.9431 7.3429 2.4476 2.239
IMR-5 GDSC1; GDSC2 5.0465 8.0729 2.1832 3.4731
GI-ME-N GDSC1; GDSC2 5.066 12.6216 0.0333 15.1388
SJNB-5 GDSC1; GDSC2 5.0839 8.2574 2.1219 3.7453
MHH-NB-11 GDSC2 5.1408 7.0059 2.6852 0.9451
SJNB-17 GDSC2 5.4289 7.5193 2.6119 0.9893
SJNB-7 GDSC1; GDSC2 5.444 11.3338 0.9166 9.7576
CHP-212 GDSC1; GDSC2; CTRP2 5.9891 6.7228 5.9063 4.6503
SK-N-AS GDSC1; GDSC2; CTRP2 6.057 6.6179 6.0103 4.0684
NH-6 CTRP2 7.2762 12.5164 4.2165 9.0149
KP-N-YN GDSC1; GDSC2; CTRP2 7.586 9.7398 5.7929 2.1129
SK-N-SH GDSC1; GDSC2; CTRP2 8.3617 13.0096 4.7536 5.1671
NB1 GDSC1; GDSC2; CTRP2 8.5361 12.7786 4.9734 4.0935
CHP-126 GDSC1; GDSC2; CTRP2 8.5527 10.4602 5.9952 0.6079
SK-N-FI GDSC1; GDSC2; CTRP2 8.7452 10.3743 6.1085 0.2818
Kelly GDSC1; GDSC2; CTRP2 8.8434 10.4444 6.1212 0.2314
⏷ Show the Full List of 35 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Biliary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuCC-T1 GDSC1; GDSC2; CTRP2 4.9995 6.2132 4.9459 11.1269
SNU-869 CTRP2 6.1269 6.6501 6.0779 3.6121
SNU-1079 CTRP2 6.3668 7.7495 5.846 3.9258
HuH-28 CTRP2 7.5138 10.1751 5.5401 3.2016
SNU-478 CTRP2 7.9697 13.8311 4.0863 8.3988
SNU-1196 CTRP2 8.7906 13.1333 4.9657 3.8234
SNU-308 CTRP2 8.9319 15.4742 3.9591 7.4912
⏷ Show the Full List of 7 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 84 Cell Line(s) in Breast Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Hs 578Bst CTRP2 -0.0017 3.4943 -2.7687 7.9283
HCC2157 GDSC1; GDSC2 2.8349 3.9372 2.552 6.5041
COLO 824 GDSC1; GDSC2 3.221 5.6296 2.083 8.1415
Evsa-T GDSC1; GDSC2 3.5547 5.8934 2.2246 6.2991
Hs 578T GDSC1; GDSC2 3.5956 6.1686 2.1197 6.8506
MDA-MB-415 GDSC1; GDSC2 3.6785 6.2638 2.1366 6.5284
UACC-812 GDSC2 3.8383 6.7341 2.0247 6.8244
MFM-223 GDSC1; GDSC2 4.0215 6.5961 2.2249 5.1549
OCUB-M GDSC1; GDSC2 4.0444 6.9089 2.0891 5.9353
MDA-MB-453 GDSC1; GDSC2; CTRP2 4.0836 4.9296 4.0826 17.0438
HCC1569 GDSC1; GDSC2; CTRP2 4.1443 6.3951 3.9797 17.2063
HCC1187 GDSC1; GDSC2 4.168 8.2015 1.5463 8.9577
EFM-192A GDSC1; GDSC2 4.2238 6.6157 2.3524 3.958
MCF-7 GDSC1; GDSC2; CTRP2; CTRP1 4.2824 9.8173 2.8253 21.1483
MDA-MB-436 GDSC1; GDSC2 4.2862 6.6393 2.3815 3.6646
MDA-MB-330 GDSC1; GDSC2 4.4927 7.0248 2.3314 3.5728
MDA-MB-157 GDSC1; GDSC2; CTRP2 4.6003 5.6956 4.5841 13.6556
HCC2218 GDSC1; GDSC2; CTRP2 4.6373 6.9071 4.3769 14.2761
BT-483 GDSC1; GDSC2 4.6974 9.3005 1.3868 8.69
YMB-1-E GDSC2 4.7047 6.6818 2.6063 1.7591
MDA-MB-175-VII GDSC1; GDSC2 4.7076 6.6642 2.6154 1.7104
HCC1599 GDSC2 4.809 9.6048 1.3168 8.8526
KPL-1 CTRP2 4.8307 5.3073 4.8306 12.0685
EFM-19 GDSC1; GDSC2 4.984 11.3984 0.571 12.5971
MRK-nu-1 GDSC1; GDSC2 5.0531 6.6752 2.7757 0.6781
CAL-120 GDSC1; GDSC2; CTRP2 5.1471 6.1636 5.1121 10.0808
DU4475 GDSC1; GDSC2; CTRP2 5.1797 7.0333 4.9249 10.6567
HCC70 GDSC1; GDSC2 5.2156 7.3262 2.5914 1.2569
MDA-MB-361 GDSC1; GDSC2; CTRP2 5.4437 13.8013 2.0215 21.1963
UACC-893 GDSC1; GDSC2 5.5595 8.1228 2.4306 1.6041
AU565 GDSC1; GDSC2; CTRP2 5.7255 16.7765 -1.5226 18.2102
HCC1954 GDSC1; GDSC2; CTRP2 5.9572 9.3238 4.696 9.6067
BT-20 GDSC1; GDSC2; CTRP2 5.9849 9.0706 4.8455 8.9262
CAL-85-1 GDSC1; GDSC2; CTRP2 6.0869 7.019 5.9043 4.3794
HCC1806 GDSC1; GDSC2; CTRP2 6.1014 9.0373 4.9697 8.1512
BT-549 GDSC1; GDSC2; CTRP2 6.2636 15.1353 2.0773 19.2171
HCC1419 GDSC1; GDSC2; CTRP2 6.5821 7.5011 6.1627 2.1429
BT-474 GDSC1; GDSC2; CTRP2 7.214 12.1478 4.3514 8.5674
HMC-1-8 CTRP2 7.5378 17.3103 2.036 16.8787
CAL-148 GDSC2; CTRP2 7.6441 10.4878 5.478 3.2698
HDQ-P1 GDSC1; GDSC2; CTRP2 7.7659 11.59 5.0319 4.8859
HCC1143 GDSC1; GDSC2; CTRP2 7.9433 13.9766 3.996 8.8025
T-47D GDSC1; GDSC2; CTRP2 8.0463 20.2968 0.948 19.4475
HCC38 GDSC1; GDSC2; CTRP2 8.419 13.0479 4.7728 5.0162
CAMA-1 GDSC1; GDSC2; CTRP2 8.4975 10.541 5.9379 0.7908
ZR-75-1 CTRP2 8.5568 10.6067 5.939 0.7517
HCC1428 GDSC1; GDSC2; CTRP2 8.6057 13.4598 4.6992 5.0608
HCC202 GDSC1; CTRP2 8.6064 11.133 5.7469 1.2762
CAL-51 GDSC1; GDSC2; CTRP2 8.7132 10.5039 6.0474 0.4121
ZR-75-30 GDSC1; GDSC2; CTRP2 8.9276 12.0323 5.5306 1.704
MDA-MB-468 GDSC1; GDSC2; CTRP2 8.9766 13.2866 5.0062 3.4683
JIMT-1 GDSC1; GDSC2; CTRP2 9.1053 14.5977 4.4832 5.2654
MDA-MB-231 GDSC1; GDSC2; CTRP2 9.1208 13.213 5.1216 2.9081
HCC1937 GDSC1; GDSC2; CTRP2 9.3932 11.3218 6.0165 0.2494
HCC1395 GDSC1; GDSC2; CTRP2 9.408 11.2816 6.0363 0.2177
HCC1500 GDSC1; GDSC2; CTRP2 10.5241 19.8491 2.927 9.1939
BT 239 CTRP2 2.9566 4.2431 2.9544 24.5485
BT 231 CTRP2 3.7382 5.9583 3.6303 19.7079
BT 286 CTRP2 3.8159 4.906 3.8126 18.8331
BT 440 CTRP2 3.8198 5.8564 3.7357 19.0824
BT 428 CTRP2 3.8488 4.63 3.8485 18.6039
BT 245 CTRP2 3.8552 5.0335 3.8493 18.58
BT 228 CTRP2 3.8772 4.5199 3.8772 18.4141
BT 271 CTRP2 3.8882 4.6994 3.8878 18.3423
BT 216 CTRP2 3.916 4.8566 3.9145 18.1608
BT 172 CTRP2 3.9939 5.0254 3.9906 17.6485
BT 416 CTRP2 4.1152 5.5156 4.0916 16.9093
BT 340 CTRP2 4.1791 4.8194 4.179 16.4051
BT 159 CTRP2 4.1854 4.5644 4.1854 16.363
BT 131 CTRP2 4.2923 5.013 4.2918 15.653
BT 422 CTRP2 4.5093 5.1394 4.5089 14.2084
BT 139 CTRP2 5.2905 6.9682 5.0671 9.8054
BT 187 CTRP2 6.174 8.0043 5.5411 5.6243
BT 112 CTRP2 7.526 9.793 5.7298 2.4334
BT 145 CTRP2 7.614 12.6638 4.3991 7.6981
BT 320 CTRP2 7.8615 8.8808 6.3058 0.216
BT 328 CTRP2 7.9465 9.3744 6.151 0.5468
BT 232 CTRP2 8.0016 10.3762 5.7509 1.8022
BT 504 CTRP2 8.1112 9.7623 6.0715 0.6635
BT 330 CTRP2 8.277 9.6213 6.199 0.2728
BT 224 CTRP2 8.4181 12.0829 5.2222 3.2911
BT 333 CTRP2 8.5048 9.6907 6.2612 0.1125
BT 179 CTRP2 8.7015 13.1548 4.9016 4.1678
BT164 CTRP2 8.7016 14.4512 4.2932 6.5118
⏷ Show the Full List of 84 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Tongue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
YD-38 CTRP2 8.339 9.2856 6.341 0.0555
Cancer Drug Sensitivity Data Curated from 68 Cell Line(s) in Central Nervous System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
KNS-60 CTRP2 3.2012 5.4834 3.1283 23.16
LNZTA3WT4 GDSC1 3.3257 10.4399 -0.9338 19.8298
PFSK-1 GDSC1; GDSC2 3.4753 5.7513 2.2326 6.4631
MOG-G-CCM GDSC1; GDSC2 3.8879 8.9848 0.9472 13.2213
SF268 GDSC1; GDSC2; CTRP2 3.8913 4.7359 3.8907 18.322
SF539 GDSC1; GDSC2; CTRP2 3.931 4.583 3.9309 18.0562
U-251MG GDSC1; GDSC2; CTRP2 3.9514 5.4162 3.9283 17.9975
AM-38 GDSC1; GDSC2 4.2136 10.9962 0.2002 16.4138
MOG-G-UVW GDSC1; GDSC2 4.2502 6.8459 2.2605 4.451
D-542MG GDSC1; GDSC2 4.2517 6.3403 2.4993 3.0445
D-336MG GDSC1; GDSC2 4.3155 7.8512 1.8223 6.9476
D-392MG GDSC1; GDSC2 4.3986 6.5981 2.4704 2.948
LN-229 GDSC1; GDSC2; CTRP2; CTRP1 4.5602 5.8603 4.5262 13.9828
M059J GDSC1; GDSC2 4.6093 6.6471 2.57 2.0732
H4 GDSC1; GDSC2 4.7139 7.5837 2.209 3.8775
SK-MG-1 GDSC1; GDSC2 4.7859 6.9154 2.5486 1.9403
CAS-1 GDSC1; GDSC2; CTRP2 4.7981 5.8295 4.78 12.3458
GB-1 GDSC1; GDSC2; CTRP2 4.8957 5.758 4.8866 11.6657
D-263MG GDSC1; GDSC2 4.9026 10.5383 0.9311 10.829
Daoy GDSC1; GDSC2; CTRP2 4.9274 5.916 4.908 11.4892
SF126 GDSC1; GDSC2; CTRP2 4.9289 5.5013 4.9282 11.4166
KS-1 [Human Krukenberg tumour] GDSC1; GDSC2 5.1025 8.0521 2.2241 3.1693
NMC-G1 GDSC1; GDSC2; CTRP2 5.1644 5.7535 5.1623 9.8538
SNB-75 GDSC1; GDSC2; CTRP2 5.3088 9.0058 4.2248 13.0609
KG-1-C CTRP2 5.3164 8.3648 4.5256 11.8364
LN-405 GDSC1; GDSC2 5.4655 8.4707 2.2382 2.5986
Onda 10 GDSC1; GDSC2 5.5026 7.3301 2.7157 0.5854
KNS-81-FD GDSC1; GDSC2 5.5285 7.3261 2.7278 0.5354
GI-1 GDSC1; GDSC2 5.573 9.1072 2.0199 3.5513
D-423MG GDSC1; GDSC2 5.609 7.9577 2.5199 1.1936
SW1088 GDSC1; GDSC2; CTRP2 5.6641 8.6233 4.7535 10.0536
D-502MG GDSC1; GDSC2 5.7405 8.6149 2.3161 1.9182
KINGS-1 GDSC1; GDSC2 5.837 7.8204 2.6688 0.542
D-566MG GDSC1; GDSC2 5.8997 7.9052 2.6626 0.5281
YKG-1 GDSC1; GDSC2; CTRP2 6.2078 6.5864 6.1823 2.9902
Hs 683 GDSC1; GDSC2; CTRP2 6.2103 6.5839 6.1856 2.9707
KNS-42 GDSC1; GDSC2; CTRP2 6.2235 6.6503 6.1833 2.9383
GaMG GDSC1; GDSC2; CTRP2; CTRP1 6.4926 9.6868 4.9946 7.2228
D-245MG GDSC2 6.5017 9.5577 2.2889 1.3502
D283 Med GDSC1; GDSC2; CTRP2 6.5039 7.9418 5.8749 3.5096
D-247MG GDSC1; GDSC2 6.5606 8.528 2.6893 0.2382
Onda 11 GDSC1; GDSC2 6.8074 8.8014 2.6832 0.1936
42-MG-BA GDSC1; GDSC2; CTRP2 7.336 11.1094 4.9584 5.8488
KNS-81 CTRP2 7.7777 22.3568 -0.2889 23.2914
SF295 GDSC1; GDSC2; CTRP2 7.8523 11.2649 5.2462 3.9068
SNU-489 CTRP2 7.8552 9.4786 6.0633 0.8721
KALS-1 GDSC1; GDSC2; CTRP2 7.8733 16.24 2.8279 13.4519
CCF-STTG1 CTRP2 7.9821 9.3961 6.1588 0.5044
U-87MG ATCC GDSC1; GDSC2; CTRP2 8.1029 9.607 6.1299 0.5109
LN-18 GDSC1; GDSC2; CTRP2 8.1226 9.0829 6.3336 0.0971
SNU-626 CTRP2 8.148 10.1547 5.9268 1.0709
SNU-738 CTRP2 8.1667 9.8957 6.0436 0.7063
SNU-201 CTRP2 8.2636 9.3386 6.2959 0.1167
GMS-10 CTRP2 8.3736 9.5942 6.2466 0.1607
DK-MG GDSC1; GDSC2; CTRP2 8.3877 13.4736 4.5501 5.9325
A-172 GDSC1; GDSC2; CTRP2 8.4255 10.9059 5.7505 1.4095
TM-31 CTRP2 8.5024 9.4969 6.3264 0.0492
U-118MG GDSC1; GDSC2; CTRP2 8.5173 10.12 6.1108 0.3587
SNU-1105 CTRP2 8.5311 9.817 6.2267 0.1519
ONS-76 GDSC1; GDSC2; CTRP2 8.6677 11.8802 5.4579 2.1755
YH-13 GDSC1; GDSC2; CTRP2 8.7771 12.4548 5.2647 2.746
M059K CTRP2 8.7782 17.4199 2.9144 11.6622
8-MG-BA GDSC1; GDSC2; CTRP2 8.7785 10.599 6.0386 0.4042
DBTRG-05MG GDSC1; GDSC2; CTRP2 8.8382 10.762 6.002 0.457
T98G GDSC1; GDSC2; CTRP2 8.8543 12.3566 5.3514 2.366
GOS-3 CTRP2 8.8546 11.7527 5.6117 1.5056
Becker GDSC1; GDSC2; CTRP2 9.0674 11.3129 5.8889 0.607
SW1783 GDSC1; GDSC2; CTRP2 9.0797 11.0117 6.0073 0.3556
⏷ Show the Full List of 68 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Digestive System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TGBC24TKB GDSC1; GDSC2 3.3114 4.876 2.5361 5.0061
ETK-1 GDSC1; GDSC2 3.4426 8.0923 1.0366 13.9426
TGBC1TKB GDSC1; GDSC2 4.1316 7.0564 2.0789 5.8007
Cancer Drug Sensitivity Data Curated from 22 Cell Line(s) in Endometrium Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HEC-151 CTRP2; CTRP1 3.5182 4.6034 3.5165 20.8091
MFE-296 GDSC1; GDSC2; CTRP2 4.1517 5.6899 4.113 16.7175
HEC-1-A CTRP2 4.1958 5.3154 4.1875 16.3211
JHUEM-2 CTRP2; CTRP1 4.3959 5.1842 4.3946 14.966
KLE GDSC1; GDSC2; CTRP2; CTRP1 4.4753 7.0285 4.162 15.5457
MFE-280 GDSC1; GDSC2 5.3507 17.9365 -2.3712 23.8818
EFE-184 CTRP2 5.966 8.8309 4.9444 8.5607
JHUEM-1 CTRP2 6.0025 6.4926 5.9786 4.3504
JHUEM-3 CTRP2 6.0865 10.8371 4.0664 11.9306
MFE-319 GDSC1; GDSC2; CTRP2 6.2058 6.7108 6.146 3.1275
ESS-1 GDSC1; GDSC2; CTRP2 7.7079 10.7451 5.3978 3.5011
JHUEM-7 CTRP2 7.8479 9.519 6.0424 0.9454
RL95-2 GDSC1; GDSC2; CTRP2 8.4719 9.8467 6.1935 0.2184
HEC-59 CTRP2; CTRP1 8.4832 10.2283 6.0551 0.4974
HEC-1-B CTRP2 8.5123 10.2494 6.0595 0.4731
HEC-6 CTRP2 8.5201 9.905 6.1911 0.2085
EN GDSC1; GDSC2; CTRP2 8.537 10.2674 6.0632 0.4535
HEC-265 CTRP2 8.743 29.6806 -3.1753 27.6305
HEC-108 CTRP2; CTRP1 8.7962 9.9721 6.2681 0.0633
AN3-CA GDSC1; GDSC2; CTRP2 10.1151 16.4391 4.2474 4.9858
HEC-50B CTRP2 13.2862 24.822 2.3118 8.1267
Ishikawa (Heraklio) 02 ER- CTRP2; CTRP1 8.1005 8.9581 6.3687 0.0615
⏷ Show the Full List of 22 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 40 Cell Line(s) in Kidney Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TUHR14TKB CTRP2 2.7169 10.2342 1.0356 31.541
SW13 GDSC1; GDSC2 3.6698 5.7216 2.3982 4.9117
UO-31 GDSC1; GDSC2; CTRP2 3.8683 4.818 3.8669 18.4783
KTCTL-13 GDSC1; GDSC2 3.8837 6.5546 2.1465 5.9574
LB996-RCC GDSC1; GDSC2 4.0189 6.7896 2.129 5.7489
A-704 GDSC1; GDSC2 4.103 7.5833 1.8019 7.5591
RCC10RGB GDSC2; CTRP2; CTRP1 4.2197 5.0682 4.2183 16.1393
KTCTL-195 GDSC1; GDSC2 4.4821 6.981 2.3451 3.5133
KTCTL-140 GDSC1; GDSC2 4.5673 7.2544 2.2712 3.7832
HA7-RCC GDSC1; GDSC2 4.8941 9.7255 1.3166 8.6718
SN12C GDSC1; GDSC2 4.9951 8.4998 1.9589 4.7961
BFTC-909 GDSC1; GDSC2; CTRP2 5.1018 5.886 5.0924 10.2951
BB65-RCC GDSC1; GDSC2 5.1071 10.9185 0.8887 10.6134
KTCTL-26A GDSC1; GDSC2 5.3447 7.2535 2.6784 0.8107
NCC021 GDSC1; GDSC2 5.5 7.5986 2.6123 0.933
TK-10 GDSC1; GDSC2 5.5231 8.3885 2.3026 2.2194
KTCTL-1M GDSC1; GDSC2 5.5233 7.506 2.6579 0.7572
KTCTL-21 GDSC1; GDSC2 5.757 8.6781 2.298 1.9806
LB2241-RCC GDSC1; GDSC2 5.7987 8.0845 2.5538 0.9233
SW156 GDSC1; GDSC2 5.9783 7.8537 2.7115 0.3729
LB1047-RCC GDSC1; GDSC2 6.0384 8.6249 2.4488 1.1202
VMRC-RCZ GDSC1; GDSC2; CTRP2 6.07 6.6631 6.0123 4.0218
CAL-54 GDSC1; GDSC2; CTRP2 6.0854 6.7662 5.9971 4.0318
KMRC-2 CTRP2 6.0901 6.5376 6.0649 3.7722
KMRC-3 CTRP2 6.2851 10.281 4.5183 9.6389
NCC010 GDSC1; GDSC2 6.3853 9.1903 2.3804 1.1125
RXF 393L GDSC1; GDSC2 6.4776 9.0515 2.471 0.7689
TUHR4TKB CTRP2 6.8649 9.0935 5.598 3.9838
TUHR10TKB CTRP2 7.5965 9.2478 6.024 1.2406
SNU-1272 CTRP2 8.2265 13.2908 4.5289 6.242
A-498 GDSC1; GDSC2; CTRP2 8.6091 11.4495 5.6137 1.7014
769-P GDSC1; GDSC2; CTRP2 8.6365 14.1841 4.3771 6.2725
VMRC-RCW GDSC2; CTRP2 8.8063 11.1898 5.8204 0.9222
KMRC-20 GDSC1; GDSC2; CTRP2 8.8486 14.3979 4.4142 5.8492
ACHN GDSC1; GDSC2; CTRP2 8.965 11.7359 5.6734 1.2366
OS-RC-2 GDSC1; GDSC2; CTRP2 9.135 10.9997 6.0334 0.2923
KMRC-1 GDSC1; GDSC2; CTRP2 9.1882 16.3897 3.6934 8.1547
786-O GDSC1; GDSC2; CTRP2 10.2212 17.5035 3.8264 6.3726
Caki-1 GDSC1; GDSC2; CTRP2 13.5263 26.0604 1.8944 9.1322
Caki-2 CTRP2 13.8514 24.715 2.6724 6.5213
⏷ Show the Full List of 40 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 61 Cell Line(s) in Large Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
COLO 320HSR GDSC1; GDSC2 1.6476 3.0912 1.5521 17.2989
LS180 GDSC1; GDSC2; CTRP2; CTRP1 3.6018 4.3468 3.6017 20.2473
T84 GDSC1; GDSC2; CTRP2 3.6219 5.4125 3.5828 20.2449
SW1463 GDSC1; GDSC2 3.7215 6.0626 2.2687 5.5924
SNU-C5 GDSC1; GDSC2; CTRP2; CTRP1 3.7228 5.012 3.7147 19.4688
DiFi GDSC1; GDSC2 3.733 6.0943 2.2617 5.6077
HT115 GDSC1; GDSC2; CTRP1 3.8211 4.6662 3.8205 20.772
NCI-H747 GDSC1; GDSC2; CTRP2 3.8615 5.4745 3.829 18.6279
HCC2998 GDSC1; GDSC2 3.8791 7.4359 1.7088 8.6794
CaR-1 GDSC1; GDSC2 4.0069 6.045 2.4803 3.6356
HT-55 GDSC1; GDSC2; CTRP2; CTRP1 4.1019 5.2809 4.0926 16.9495
CCK-81 GDSC1; GDSC2 4.1458 6.6464 2.286 4.514
SW1116 GDSC1; GDSC2; CTRP2 4.1743 5.625 4.1437 16.5396
SW620 GDSC1; GDSC2; CTRP2; CTRP1 4.223 5.9374 4.1558 16.341
SW480 CTRP1 4.2373 5.2731 4.2306 33.2898
RCM-1 [Human ESC] GDSC1; GDSC2; CTRP2; CTRP1 4.3147 5.3544 4.3079 15.525
GP5d GDSC1; GDSC2 4.3216 6.19 2.6105 2.2952
CW-2 GDSC1; GDSC2; CTRP2; CTRP1 4.3819 5.554 4.3668 15.1056
SNU-C4 CTRP2; CTRP1 4.3935 5.1757 4.3922 14.982
SW837 GDSC1; GDSC2 4.4276 9.3079 1.1929 10.4335
NCI-H508 GDSC1; GDSC2; CTRP2; CTRP1 4.4513 9.8464 2.9824 20.1139
SNU-81 GDSC1; GDSC2; CTRP1 4.4707 5.7218 4.4426 15.9593
SNU-61 GDSC1; GDSC2; CTRP2; CTRP1 4.5059 6.3828 4.3763 14.6772
OUMS-23 CTRP2 4.5488 10.7841 2.6451 21.1252
COLO 678 GDSC1; GDSC2; CTRP2; CTRP1 4.5559 10.7688 2.6593 21.0547
SNU-C2B GDSC1; GDSC2 4.6189 8.0162 1.9477 5.5628
COLO 320 CTRP2; CTRP1 4.6718 8.9446 3.6111 17.1151
LoVo GDSC1; GDSC2; CTRP2; CTRP1 4.6755 6.3438 4.5695 13.4658
SNU-175 GDSC2; CTRP1 4.698 5.9733 4.6532 14.3037
SNU-283 GDSC2 4.7091 6.9135 2.5079 2.2538
KM12 GDSC1; GDSC2; CTRP2; CTRP1 4.7494 10.4167 3.0143 19.231
SNU-1040 GDSC1; CTRP1 4.7914 5.6493 4.7832 14.5151
HT-29 GDSC1; GDSC2; CTRP2; CTRP1 4.8425 8.7714 3.8621 15.6863
CL-40 CTRP1 4.9228 5.7915 4.9105 23.5378
CL-34 CTRP1 4.9602 5.8076 4.9484 23.0002
SW948 GDSC1; GDSC2; CTRP2; CTRP1 4.9812 8.3623 4.1839 15.8921
MDST8 GDSC1; GDSC2; CTRP2; CTRP1 5.0025 6.3905 4.9149 11.226
HCT 8 CTRP2; CTRP1 5.0277 6.0265 5.0024 10.8422
SW626 GDSC1; GDSC2 5.0884 7.8478 2.3063 2.7602
DLD-1 CTRP2 5.1501 5.5984 5.1498 9.9428
LS1034 GDSC1; GDSC2; CTRP2 5.7127 7.9204 5.1268 8.4274
CL-11 GDSC1; GDSC2; CTRP2 5.9281 8.8128 4.9173 8.7595
SNU-C1 GDSC1; GDSC2; CTRP2 5.9404 12.9541 2.8849 16.9581
C2BBe1 GDSC1; GDSC2; CTRP2 5.9728 6.8297 5.8535 4.8934
HCT 116 GDSC1; GDSC2; CTRP2; CTRP1 6.1191 13.8971 2.5711 17.7535
SW48 GDSC1; GDSC2; CTRP2 6.528 12.0599 3.8387 11.9603
SNU-503 CTRP2 6.9993 16.0104 2.2534 17.1284
HCT 15 GDSC1; GDSC2; CTRP2 7.3037 9.6382 5.6545 3.0416
HCC-56 CTRP2 7.8361 8.7562 6.3416 0.1572
SW1417 GDSC1; GDSC2; CTRP2 8.117 13.2934 4.4524 6.706
LS513 GDSC1; CTRP2 8.1282 11.5203 5.3038 3.3263
LS123 GDSC1; GDSC2; CTRP2; CTRP1 8.1845 10.004 6.0078 0.7971
SK-CO-1 GDSC1; GDSC2; CTRP2 8.2344 12.6635 4.834 5.0212
SNU-1033 CTRP2 8.2437 12.5561 4.8911 4.7839
LS411N GDSC1; GDSC2; CTRP2 8.4294 9.4535 6.3158 0.0666
SNU-C2A CTRP2 8.4353 20.7582 1.0184 18.5694
COLO205 GDSC1; GDSC2; CTRP2 8.506 9.8418 6.2084 0.1848
SNU-407 GDSC1; GDSC2; CTRP2 8.5682 12.9786 4.9005 4.3329
NCI-H716 GDSC1; GDSC2; CTRP2 8.6976 10.4745 6.052 0.4088
GP2d CTRP2 9.0283 15.837 3.8503 7.7764
RKO GDSC1; GDSC2; CTRP2; CTRP1 10.1737 18.4905 3.3403 8.1735
⏷ Show the Full List of 61 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Leukemia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MO-T GDSC1; GDSC2 4.3127 6.8026 2.3218 3.9638
Cancer Drug Sensitivity Data Curated from 25 Cell Line(s) in Liver Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SNU-761 CTRP2 2.3228 9.4099 0.964 32.9908
HuH-6 CTRP2 3.8091 6.691 3.5372 19.8184
SNU-398 GDSC1; GDSC2; CTRP2; CTRP1 3.9012 5.1991 3.89 18.2918
SNU-182 CTRP2 4.0325 5.6486 3.9914 17.5193
Li-7 CTRP2 4.1547 5.8406 4.0971 16.7622
HLE GDSC1; GDSC2 4.6736 8.1735 1.909 5.6817
Huh-7 GDSC1; GDSC2 4.8381 6.65 2.6873 1.2211
JHH-7 GDSC1; GDSC2 4.8396 7.3008 2.4096 2.5793
Hep-G2/C3A GDSC1; GDSC2 4.8665 6.4404 2.7851 0.7875
Hep-G2 CTRP2; CTRP1 4.9899 6.4128 4.8963 11.3311
JHH-5 CTRP2 6.0241 10.6972 4.0801 12.0078
SNU-878 CTRP2 6.5943 9.2816 5.2834 5.8092
JHH-6 GDSC1; GDSC2; CTRP2; CTRP1 6.6301 10.0378 4.9354 7.2001
PLC/PRF/5 CTRP2 6.8663 9.1563 5.5679 4.1071
JHH-2 GDSC1; GDSC2; CTRP2 7.8318 14.7507 3.5328 10.8233
SNU-449 GDSC1; GDSC2; CTRP2; CTRP1 8.1783 14.4994 3.9098 8.7784
SNU-475 CTRP2 8.2799 9.4374 6.2671 0.1536
SK-HEP-1 GDSC1; GDSC2; CTRP2 8.407 9.7761 6.1938 0.2378
HLF CTRP2 8.5067 10.4302 5.9864 0.6556
JHH-1 GDSC1; GDSC2; CTRP2 8.5068 12.9976 4.8529 4.5923
JHH-4 GDSC1; GDSC2; CTRP2 8.6328 12.9455 4.956 4.0436
HuH-1 GDSC1; GDSC2; CTRP2 8.7195 10.209 6.1583 0.2064
Hep 3B2.1-7 GDSC1; GDSC2; CTRP2 8.7301 10.2242 6.1569 0.2057
SNU-423 GDSC1; GDSC2; CTRP2 9.1342 16.7059 3.5064 8.9345
SNU-387 GDSC1; GDSC2; CTRP2 10.1332 18.5695 3.2777 8.4484
⏷ Show the Full List of 25 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 227 Cell Line(s) in Lung Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NCI-H1648 GDSC1; GDSC2 2.6518 4.6984 2.0183 10.4334
SCLC-21H CTRP1 2.8931 3.6825 2.893 52.4455
NCI-H835 GDSC1; GDSC2 3.2171 4.8914 2.4482 5.8443
Calu-3 GDSC1; GDSC2; CTRP2 3.2268 4.0833 3.2267 22.7435
NCI-H69 GDSC1; GDSC2 3.3525 6.3079 1.8544 9.195
NCI-H211 GDSC1; GDSC2; CTRP2 3.3695 4.3322 3.3691 21.7945
NCI-H209 GDSC1; GDSC2 3.459 5.2374 2.4758 4.9717
NCI-H1963 GDSC2; CTRP1 3.5249 5.4099 3.4766 23.1981
NCI-H524 GDSC1; GDSC2 3.5312 5.0445 2.6282 3.8204
NCI-H1930 CTRP1 3.5405 13.848 -1.5975 32.9628
NCI-H720 GDSC1; GDSC2 3.5553 6.9553 1.6959 9.6151
NCI-H1666 GDSC1; GDSC2; CTRP2 3.5567 7.5884 2.9766 22.6113
UMC-11 GDSC1; GDSC2 3.572 9.7305 0.3236 17.5435
NCI-H187 GDSC1 3.58 4.899 1.87 0.8702
NCI-H1581 GDSC1; GDSC2; CTRP2 3.6065 4.6866 3.6045 20.2226
NCI-H2342 GDSC1; GDSC2; CTRP2; CTRP1 3.6607 4.582 3.66 19.8573
NCI-H1836 GDSC1; GDSC2; CTRP1 3.7125 4.5246 3.7122 21.5934
NCI-H2106 CTRP2 3.7214 4.9208 3.7162 19.4683
Ms-1 GDSC1; GDSC2 3.7303 8.526 1.0519 13.0405
NCI-H847 GDSC1; GDSC2 3.7941 6.1764 2.2666 5.4275
EKVX GDSC1; GDSC2; CTRP2 3.8106 6.0262 3.6959 19.2497
LK-2 GDSC1; GDSC2 3.8151 5.9081 2.4133 4.4677
NCI-H1304 GDSC1 3.8153 6.6288 1.249 4.3311
COR-L279 GDSC1; GDSC2 3.821 5.8949 2.424 4.388
NCI-H1048 GDSC1; GDSC2 3.8377 5.6953 2.5327 3.6814
NCI-H1793 GDSC1; GDSC2; CTRP2 3.8711 4.9603 3.8674 18.4671
NCI-H2373 GDSC1; GDSC2 3.8978 5.7274 2.5586 3.3927
NCI-H2087 GDSC1; GDSC2; CTRP2 3.9084 5.9587 3.8139 18.529
NCI-H1385 CTRP2 3.9302 4.8911 3.9284 18.0671
HOP-62 GDSC1; GDSC2; CTRP2 3.9341 4.8106 3.9332 18.0386
NCI-H2286 CTRP1 3.9482 5.6807 2.8064 5.393
NCI-H82 GDSC1; GDSC2 3.9543 8.8644 1.0585 12.3998
HOP-92 GDSC1; GDSC2; CTRP2 3.9804 5.616 3.9399 17.8638
DMS 454 CTRP2 3.9872 5.257 3.9757 17.7206
DMS 53 GDSC1; GDSC2; CTRP2 3.9929 5.3499 3.9762 17.6999
HCC1359 CTRP1 4.0056 4.6218 4.0056 36.5526
NCI-H1573 GDSC1; GDSC2; CTRP2 4.0206 4.7598 4.0203 17.4604
NCI-H2066 GDSC1; GDSC2 4.0279 5.9841 2.5233 3.3347
NCI-H1876 GDSC1; GDSC2; CTRP1 4.0433 4.806 4.0428 19.0894
IST-SL1 GDSC1; GDSC2 4.0469 6.6012 2.2401 5.0054
NCI-H841 GDSC1; GDSC2; CTRP2; CTRP1 4.0799 7.4978 3.5735 18.883
COR-L51 CTRP2; CTRP1 4.1124 5.2856 4.1031 16.8799
NCI-H596 GDSC1; GDSC2; CTRP1 4.127 4.9172 4.1262 18.4569
NCI-H1105 GDSC1; GDSC2; CTRP1 4.1299 4.8632 4.1294 18.4339
Lu-135 GDSC1; GDSC2 4.1314 6.0611 2.5538 2.9519
PaCa-3 GDSC1; GDSC2 4.1648 7.2448 2.0108 6.1412
NCI-H2081 GDSC1; GDSC2; CTRP2; CTRP1 4.1754 5.9852 4.097 16.6966
Lu-165 GDSC1; GDSC2 4.1843 10.5373 0.4053 15.4283
CAL-12T GDSC1; GDSC2; CTRP2; CTRP1 4.1857 5.483 4.1676 16.4215
NCI-H2595 GDSC1; GDSC2 4.1885 7.1254 2.085 5.6381
COLO 699 CTRP2; CTRP1 4.1939 5.4192 4.1802 16.352
NCI-H2804 GDSC1; GDSC2 4.1988 6.4031 2.4364 3.5108
NCI-H146 GDSC1; GDSC2 4.2039 6.1678 2.5496 2.8421
NCI-H2731 GDSC1; GDSC2 4.2056 6.7456 2.2787 4.4335
IST-SL2 GDSC1; GDSC2 4.2096 9.3116 1.0309 11.9037
NCI-H1155 GDSC1; GDSC2; CTRP2 4.2494 6.0246 4.17 16.2074
HCC44 GDSC1; GDSC2; CTRP2 4.2879 5.8851 4.2331 15.8664
HCC2935 CTRP2; CTRP1 4.3051 5.2358 4.3017 15.5772
CPC-N GDSC1; GDSC2 4.3295 10.1796 0.6923 13.5097
NCI-H1437 GDSC1; GDSC2 4.3581 6.3862 2.543 2.6096
A-427 GDSC1; GDSC2 4.3788 12.6853 -0.5108 19.3612
NCI-H446 GDSC1; GDSC2; CTRP2 4.3823 6.3604 4.247 15.5193
T3M-10 CTRP2; CTRP1 4.4004 5.731 4.3713 15.0298
NCI-H2369 GDSC1; GDSC2 4.4045 8.8786 1.386 9.3559
COR-L321 GDSC1; GDSC2 4.428 8.1104 1.775 6.9845
COR-L32 GDSC1; GDSC2 4.4555 7.5208 2.0754 5.136
NCI-H1355 GDSC1; GDSC2; CTRP2 4.4562 6.5714 4.2758 15.1889
HCC1195 CTRP2; CTRP1 4.464 5.2652 4.4621 14.5148
NCI-H1694 GDSC1; GDSC2; CTRP1 4.4819 5.9255 4.4289 15.9713
NCI-H2591 GDSC1; GDSC2 4.492 8.0583 1.8436 6.4377
NCI-H1688 GDSC1; GDSC2 4.4948 6.0395 2.7713 1.2186
Lu-139 GDSC1 4.4995 6.6049 1.6096 1.1744
SBC-3 GDSC1; GDSC2 4.5132 6.7457 2.4714 2.7499
NCI-H1650 GDSC1; GDSC2; CTRP2 4.5157 6.4677 4.367 14.6798
NCI-H358 GDSC1; GDSC2; CTRP2 4.524 6.3438 4.4049 14.5195
NCI-H441 GDSC1; GDSC2; CTRP1 4.5395 5.9461 4.4875 15.5317
NCI-H2818 GDSC1; GDSC2 4.5693 7.6725 2.0776 4.8995
NCI-H250 GDSC2 4.5733 9.1018 1.3967 8.9068
NCI-H2722 GDSC1; GDSC2 4.6159 8.1899 1.8635 6.0641
RERF-LC-KJ GDSC1; GDSC2; CTRP1 4.6259 6.7601 2.7404 2.7503
Lu-99A GDSC1; GDSC2 4.6303 7.1098 2.3753 3.089
SBC-1 GDSC1; GDSC2 4.6422 6.5262 2.6403 1.6717
NCI-H2122 GDSC1; GDSC2; CTRP2; CTRP1 4.645 6.2007 4.5655 13.5759
HCC4006 CTRP2; CTRP1 4.6563 5.6793 4.6435 13.2717
NCI-H810 GDSC1; GDSC2; CTRP2 4.6605 6.6269 4.484 13.8168
HCC15 GDSC1; GDSC2; CTRP2; CTRP1 4.6627 5.779 4.6425 13.2539
NCI-H2171 GDSC2 4.674 6.9893 2.4547 2.587
PC-14 GDSC1; GDSC2 4.6778 6.6775 2.5939 1.8563
NCI-H2023 GDSC1; GDSC2; CTRP2; CTRP1 4.7061 6.2151 4.6288 13.1616
HARA [Human squamous cell lung carcinoma] GDSC1; GDSC2; CTRP2 4.711 5.9386 4.6769 12.9798
NCI-H3255 GDSC1; GDSC2; CTRP1 4.7249 5.8977 4.6919 14.0539
COR-L311 GDSC2 4.725 7.6707 2.1758 4.0459
NCI-H1993 GDSC1; GDSC2 4.7444 8.0402 2.0166 4.9211
NCI-H1770 GDSC1; GDSC2 4.7578 6.6018 2.6676 1.399
NCI-H510A GDSC2 4.7617 6.4579 2.7292 1.1157
NCI-H2135 GDSC1; GDSC2 4.7671 7.1838 2.4208 2.6273
NCI-H345 GDSC1; GDSC2 4.772 5.8021 2.9864 0.2088
NCI-H2227 GDSC1; GDSC2 4.7733 6.7018 2.6334 1.542
SW1271 GDSC1; GDSC2; CTRP2 4.7908 7.6501 4.2793 14.2016
NCI-H1781 GDSC1; GDSC2; CTRP1 4.7933 5.6331 4.786 13.4368
NCI-H2444 GDSC1; GDSC2; CTRP2 4.8054 6.0284 4.7659 12.3699
NCI-H2073 CTRP1 4.8122 5.8555 4.789 25.1972
SK-LU-1 GDSC1; GDSC2; CTRP2; CTRP1 4.8216 6.3389 4.7294 12.4453
HCC2108 CTRP2; CTRP1 4.8349 10.272 3.1661 18.4338
NCI-H2347 GDSC1; GDSC2 4.8354 7.7522 2.2049 3.6942
NCI-H322M GDSC1; GDSC2 4.8499 8.6131 1.8155 5.8818
NCI-H2795 GDSC1; GDSC2 4.8499 9.2562 1.5112 7.6438
NCI-H1436 GDSC1; GDSC2 4.8531 7.2359 2.4456 2.3728
HCC1438 CTRP2 4.8822 5.9294 4.8591 11.8026
RERF-LC-Sq1 GDSC1; GDSC2 4.8877 12.0179 0.1997 14.7354
LC-1/sq GDSC1; GDSC2 4.8936 8.0955 2.083 4.2757
RERF-LC-A1 CTRP2 4.899 6.2267 4.8352 11.8314
NCI-H2172 GDSC1; GDSC2; CTRP1 4.9065 5.7522 4.8963 12.5907
SBC-5 GDSC1; GDSC2; CTRP2 4.9243 6.6183 4.7742 11.9687
NCI-H2228 GDSC1; GDSC2; CTRP2 4.9319 13.3422 1.7793 23.2129
Lu-99 CTRP2 4.941 5.5534 4.9397 11.3381
HCC1171 CTRP2 4.9651 5.992 4.94 11.258
NCI-H2461 GDSC1; GDSC2 4.9874 11.7625 0.3962 13.5029
KNS-62 GDSC1; GDSC2; CTRP2 5.0165 5.5539 5.0159 10.8331
ABC-1 GDSC1; GDSC2 5.0325 6.9289 2.6662 1.1181
NCI-H1755 GDSC1; GDSC2; CTRP2; CTRP1 5.0465 9.3658 3.7977 15.4223
NCI-H1838 GDSC1; GDSC2; CTRP2 5.0663 5.8488 5.0579 10.528
COR-L23 GDSC1; GDSC2; CTRP1 5.0735 5.5787 5.0728 11.29
EMC-BAC-2 GDSC1; GDSC2 5.1274 10.588 1.0611 9.6204
NCI-H1975 GDSC1; GDSC2; CTRP2 5.131 6.8462 4.9334 10.7682
NCI-H64 GDSC2 5.1579 12.9553 -0.0636 15.3923
NCI-H513 GDSC1; GDSC2 5.1892 7.271 2.6014 1.2403
NCI-H196 GDSC1; GDSC2; CTRP2 5.2582 5.7541 5.2572 9.2259
NCI-H1693 GDSC1; GDSC2; CTRP2 5.3714 6.8504 5.1938 9.0991
LB647-SCLC GDSC1; GDSC2 5.3863 7.1518 2.7348 0.5951
Lu-134-A GDSC1; GDSC2 5.4549 9.2481 1.8911 4.4048
COR-L303 GDSC2 5.6187 6.9494 2.8954 0.1354
Calu-1 CTRP2 5.6609 8.0207 5.0292 8.9492
NCI-H2803 GDSC1; GDSC2 5.6661 7.3122 2.7864 0.3221
HCC95 CTRP2 5.6936 8.9082 4.6472 10.416
DV-90 CTRP2 5.7435 7.3797 5.395 7.2868
NCI-H3122 GDSC2 5.7731 8.0905 2.5405 0.9882
NCI-H2029 GDSC1; GDSC2; CTRP2 5.8398 7.4398 5.4695 6.7389
ChaGo-K-1 GDSC1; GDSC2; CTRP2 5.8477 9.1868 4.6603 10.0029
NCI-H290 GDSC1; GDSC2 5.851 7.8319 2.6702 0.5313
COLO 668 GDSC1; GDSC2; CTRP2; CTRP1 5.8568 7.9375 5.2635 7.517
NCI-H522 GDSC1; GDSC2; CTRP2 5.873 6.9625 5.6983 5.763
NCI-H748 GDSC2 5.8923 7.9202 2.6541 0.5548
LCLC-97TM1 GDSC1; GDSC2; CTRP2 5.93 8.4863 5.0764 8.1017
NCI-H647 GDSC2; CTRP2 5.9346 9.2607 4.7058 9.6168
NCI-H740 GDSC2 5.9401 8.7249 2.3655 1.5169
NCI-H1944 GDSC1; GDSC2; CTRP2 5.9515 9.0666 4.8162 9.1231
HCC33 GDSC2 5.9516 7.4537 2.8408 0.1449
NCI-H322 CTRP2 6.0408 6.6421 5.9862 4.2044
NCI-H2170 GDSC1; GDSC2; CTRP2 6.07 10.6344 4.1522 11.6117
SK-MES-1 GDSC1; GDSC2; CTRP2 6.0945 6.8339 5.9835 4.0559
LUDLU-1 CTRP2 6.1248 6.7083 6.0586 3.6887
NCI-H1915 GDSC1; GDSC2; CTRP2; CTRP1 6.133 6.7042 6.0688 3.6271
DMS 79 GDSC1; GDSC2; CTRP2 6.143 10.1418 4.4617 10.1731
LC-2/ad GDSC1; GDSC2 6.1527 8.0952 2.6913 0.3538
Sq-1 CTRP2; CTRP1 6.2663 7.6135 5.8171 4.2754
LK2 CTRP2 6.3252 6.6889 6.2828 2.2711
EMC-BAC-1 GDSC1; GDSC2 6.3407 8.6911 2.5491 0.6202
LCLC-103H GDSC1; GDSC2; CTRP2 6.3483 6.886 6.2337 2.3929
DMS 114 GDSC1; GDSC2; CTRP2 6.5427 10.2205 4.7705 8.0625
NCI-H292 GDSC1; GDSC2; CTRP2 6.5934 10.1553 4.8459 7.6469
NCI-H1092 GDSC1; GDSC2; CTRP2 6.6025 9.8405 5.011 6.9367
NCI-H520 GDSC1; GDSC2; CTRP2 6.6533 8.1391 5.9041 3.0883
DMS 273 GDSC1; GDSC2; CTRP2 6.7254 8.3535 5.856 3.1548
NCI-H889 CTRP2 6.7334 8.9176 5.5808 4.2946
NCI-H1341 GDSC1; GDSC2; CTRP2 6.7421 11.4308 4.3317 9.5096
COR-L88 GDSC1; GDSC2; CTRP2 6.7575 12.429 3.8454 11.4855
NCI-H2869 GDSC1; GDSC2 6.7589 8.5979 2.7349 0.1372
NCI-H2141 GDSC1; GDSC2; CTRP2; CTRP1 6.7836 13.14 3.5115 12.785
NCI-H2810 GDSC1; GDSC2 6.8145 8.928 2.6425 0.2524
NCI-H2110 GDSC1; GDSC2; CTRP2; CTRP1 6.9471 10.7556 4.8349 7.0299
NCI-H2196 GDSC2; CTRP2 7.2929 9.6143 5.6586 3.0407
MOR/CPR CTRP2 7.3028 9.035 5.9427 1.8896
NCI-H226 GDSC1; GDSC2; CTRP2 7.3159 18.6419 1.1953 20.0219
NCI-H1184 CTRP2 7.3179 14.4676 3.2785 12.7116
IA-LM GDSC1; GDSC2; CTRP2 7.4492 10.7248 5.2293 4.5551
A-549 GDSC1; GDSC2; CTRP2 7.5294 10.6367 5.3286 4.0312
NCI-H1563 GDSC1; GDSC2; CTRP2 7.5805 18.5573 1.4486 18.7411
NCI-H1651 GDSC1; GDSC2; CTRP2 7.6143 14.1393 3.671 10.6431
COR-L95 GDSC1; CTRP2 7.6535 9.8002 5.8067 1.9794
RERF-LC-Ad1 CTRP2 7.747 8.5215 6.3919 0.1004
NCI-H460 GDSC1; GDSC2; CTRP2; CTRP1 7.8 10.3114 5.6607 2.3596
COR-L105 GDSC1; GDSC2; CTRP2 8.0451 12.751 4.6645 5.9603
SHP-77 GDSC1; GDSC2; CTRP2 8.0503 10.4241 5.7572 1.7301
LOU-NH91 GDSC1; GDSC2; CTRP2 8.2513 10.2641 5.9329 0.9727
HCC1833 CTRP2; CTRP1 8.254 16.8173 2.8287 12.8104
VMRC-LCD GDSC1; GDSC2; CTRP2 8.2763 13.8971 4.2711 7.1962
NCI-H650 GDSC1; GDSC2; CTRP2 8.2783 10.9716 5.6425 1.9085
NCI-H2126 CTRP2 8.3114 9.7944 6.1481 0.3646
HCC366 GDSC1; GDSC2; CTRP2 8.3428 13.2848 4.6102 5.7568
NCI-H1339 CTRP2 8.3778 11.3747 5.5194 2.2443
NCI-H23 GDSC1; GDSC2; CTRP2 8.406 11.9323 5.2839 3.0742
NCI-H2030 GDSC1; GDSC2; CTRP2; CTRP1 8.4378 10.5541 5.9042 0.9254
Lu-65 GDSC1; GDSC2; CTRP2 8.5174 13.1465 4.7898 4.8229
NCI-H838 GDSC1; GDSC2; CTRP2 8.5282 13.037 4.848 4.5841
NCI-H2291 GDSC1; GDSC2; CTRP2 8.575 10.6175 5.943 0.7301
NCI-H1703 GDSC1; GDSC2; CTRP2 8.5774 13.0859 4.8563 4.491
LC-1/sq-SF CTRP2 8.621 12.2158 5.2821 2.8454
COR-L47 CTRP2 8.7003 17.9083 2.62 12.8517
NCI-H1373 CTRP2 8.7151 11.7083 5.5582 1.7928
SW1573 GDSC1; GDSC2; CTRP2 8.7189 13.1758 4.9025 4.1435
HCC827 GDSC1; GDSC2; CTRP2; CTRP1 8.7268 13.4262 4.7914 4.5556
NCI-H526 GDSC1; GDSC2; CTRP2 8.7372 10.4931 6.0614 0.3739
NCI-H1395 CTRP2 8.7465 11.9936 5.4513 2.124
RERF-LC-MS GDSC1; GDSC2; CTRP2 8.9664 11.4445 5.7924 0.9011
NCI-H1869 GDSC1; GDSC2; CTRP2 8.9737 11.2702 5.8646 0.7111
NCI-H2009 GDSC1; GDSC2; CTRP2 8.9903 10.7854 6.0548 0.2993
NCI-H2405 GDSC1; GDSC2; CTRP2 8.9931 10.6898 6.0904 0.2396
EPLC-272H GDSC1; GDSC2; CTRP2 8.9941 15.3303 4.0685 6.9874
NCI-H1568 GDSC1; GDSC2; CTRP2 9.1059 20.8105 1.493 16.0143
NCI-H1734 GDSC2; CTRP2 9.1494 10.9973 6.0398 0.2776
NCI-H727 GDSC1; GDSC2; CTRP2 9.2317 10.8447 6.1243 0.1418
Calu-6 GDSC1; GDSC2; CTRP2 9.3925 10.8288 6.1859 0.0645
NCI-H2085 GDSC1; GDSC2; CTRP2 9.484 11.3519 6.0397 0.1969
NCI-H1623 GDSC1; GDSC2; CTRP2 9.5224 16.1591 4.0177 6.5028
EBC-1 GDSC1; GDSC2; CTRP2 9.5254 11.3117 6.0687 0.1541
NCI-H1792 GDSC1; GDSC2; CTRP2 9.8482 14.3531 5.0184 2.5941
NCI-H1299 GDSC1; GDSC2; CTRP2 9.9988 18.021 3.4491 8.0005
HCC1588 CTRP2 10.0848 47.4347 -10.9597 34.6513
BEN GDSC1; GDSC2; CTRP2 10.8908 26.2505 0.1146 17.3671
LXF 289 GDSC1; GDSC2; CTRP2; CTRP1 11.0825 20.5588 2.9455 8.4564
HCC2279 CTRP2 11.3442 22.6139 2.1536 10.7633
NCI-H661 GDSC1; GDSC2; CTRP2 11.5563 22.9706 2.121 10.6099
NCI-H1435 GDSC1; GDSC2; CTRP2; CTRP1 11.6068 22.8677 2.2006 10.2955
RERF-LC-Ad2 CTRP2 11.7889 21.9096 2.7531 8.2976
HCC78 GDSC1; GDSC2; CTRP2 13.8178 35.9186 -2.5326 19.7108
Hs 888.Lu CTRP2 9.2448 14.8645 4.4459 5.2382
⏷ Show the Full List of 227 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Lymphoma Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CBTCi002-A GDSC1; GDSC2 3.8793 7.2353 1.8081 8.0654
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Thigh Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
H-STS CTRP2 6.9122 8.4808 5.9384 2.4836
P-STS CTRP2 8.5211 10.5104 5.9611 0.7138
SYO-1 CTRP2 8.7294 10.2627 6.1428 0.2282
Cancer Drug Sensitivity Data Curated from 31 Cell Line(s) in Soft Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Yamato-SS CTRP2 8.3348 9.5347 6.2531 0.1607
Aska-SS CTRP2 8.3605 9.5637 6.2525 0.1552
EW-8 GDSC1; GDSC2 3.3916 5.2882 2.3962 5.6619
Hs 633.T GDSC1; GDSC2 3.6567 5.5339 2.481 4.4266
Rh30 GDSC1; GDSC2 3.6992 5.9097 2.3274 5.2807
A-204 GDSC1; GDSC2; CTRP2 3.8832 5.8757 3.8007 18.6548
GCT GDSC1; GDSC2; CTRP2 3.9364 4.8496 3.9352 18.0239
KYM-1 GDSC1; GDSC2; CTRP2 4.6393 6.3419 4.5307 13.7157
RKN GDSC1; GDSC2; CTRP2; CTRP1 4.6664 5.5655 4.6599 13.1833
SW684 GDSC1; GDSC2 4.7006 6.0226 2.8752 0.5815
STS-0421 GDSC1; GDSC2 5.0353 8.3047 2.0722 4.0962
MFH-ino GDSC1; GDSC2 5.1054 10.7052 0.9901 10.0599
SW872 GDSC1; GDSC2 5.7478 14.4642 -0.3799 15.5398
VA-ES-BJ GDSC1; GDSC2 5.7617 11.9918 0.8125 9.6812
TE 617.T CTRP2 5.8021 7.1788 5.539 6.569
TE 441.T GDSC2; CTRP2 5.843 6.6057 5.78 5.5495
Rh18 GDSC1; CTRP2 5.9262 8.8493 4.8979 8.8439
MES-SA GDSC1; GDSC2; CTRP2 6.1039 6.5112 6.0848 3.659
Hs 729.T CTRP2 6.1531 6.5751 6.1253 3.3622
BT-12 CTRP2 6.5283 13.928 2.2138 13.4125
HT-1080 GDSC1; GDSC2; CTRP2; CTRP1 6.7647 10.0851 5.0229 6.5771
G-401 GDSC1; GDSC2; CTRP2 7.3231 15.4971 2.7698 14.6443
SK-LMS-1 GDSC1; GDSC2; CTRP2 7.3667 10.7752 5.1453 5.0284
G-402 GDSC1; GDSC2; CTRP2 7.7116 13.2779 4.1692 8.4761
Rh41 GDSC1; GDSC2; CTRP2 8.2144 12.8234 4.7446 5.4017
SW982 GDSC1; GDSC2; CTRP2 8.4437 9.5864 6.2753 0.107
BT-16 CTRP2 8.6612 9.7786 6.2865 0.0635
TTC-709 CTRP2 8.6646 10.4595 6.0439 0.44
Tm87-16 CTRP2 8.6835 10.3463 6.0942 0.3292
SK-UT-1 GDSC1; GDSC2; CTRP2 10.2529 16.5706 4.2678 4.7699
RD GDSC1; GDSC2; CTRP2 13.1531 22.6804 3.1802 5.6061
⏷ Show the Full List of 31 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Clivus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
U-CH1 CTRP2 8.5463 9.9388 6.189 0.2045
Cancer Drug Sensitivity Data Curated from 48 Cell Line(s) in Ovary Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
2004 CTRP2 8.7309 10.1665 6.1777 0.1747
COV434 CTRP2; CTRP1 3.2065 4.682 3.1985 22.9049
JHOS-4 GDSC2; CTRP1 3.7673 5.6809 2.6699 4.977
Caov-4 GDSC1; GDSC2 3.8353 6.4361 2.1692 5.9327
OVKATE GDSC1; GDSC2; CTRP1 3.8407 4.9849 3.8351 20.6427
OVK18 GDSC1; GDSC2; CTRP2; CTRP1 3.9346 5.2107 3.9238 18.0681
OVCAR-8 GDSC1; GDSC2; CTRP2; CTRP1 4.0061 5.1596 3.9993 17.5788
OVCAR-5 GDSC1; GDSC2; CTRP2 4.0118 4.6977 4.0116 17.5188
OVCAR-4 GDSC1; GDSC2; CTRP2; CTRP1 4.0294 8.3258 3.2039 20.413
RMUG-S CTRP1 4.0414 6.0779 3.927 36.7783
A2780 GDSC1; GDSC2; CTRP2; CTRP1 4.1872 5.7553 4.143 16.5001
ES-2 GDSC1; GDSC2 4.2105 5.9998 2.631 2.3665
TOV-21G GDSC1; GDSC2 4.32 6.5032 2.4661 3.1116
OVMANA CTRP1 4.3211 6.1502 2.8344 4.0233
TYK-nu GDSC1; GDSC2; CTRP2; CTRP1 4.3563 5.4612 4.3458 15.2605
RMG-I GDSC1; GDSC2; CTRP2; CTRP1 4.3584 10.238 2.7102 21.3759
SNU-119 CTRP2 4.3857 5.2622 4.3829 15.039
OVCAR-3 GDSC1; GDSC2 4.4588 6.9422 2.3487 3.5349
OC 314 GDSC1; GDSC2; CTRP2 4.4669 5.5252 4.4565 14.5241
OV-90 GDSC1; GDSC2; CTRP2; CTRP1 4.5376 6.3313 4.4224 14.4153
COV318 CTRP1 4.5659 5.8704 3.1001 1.4395
JHOM-1 CTRP2; CTRP1 4.76 9.7829 3.3202 18.0236
OAW42 GDSC1; GDSC2; CTRP2; CTRP1 4.8384 5.549 4.836 12.0246
JHOC-5 CTRP2; CTRP1 4.8561 5.6518 4.851 11.9158
COV362 CTRP2; CTRP1 4.9384 6.0631 4.903 11.4708
Caov-3 GDSC2; CTRP2; CTRP1 5.023 9.45 3.7354 15.7289
OV7 CTRP2; CTRP1 5.0772 5.7647 5.0731 10.4409
TOV-112D GDSC1; GDSC2; CTRP2 6.0979 19.1746 -0.0821 25.9819
DOV13 GDSC1; GDSC2; CTRP2 6.6287 10.8396 4.5334 8.8867
IGROV-1 GDSC1; GDSC2; CTRP2; CTRP1 6.6495 11.1955 4.3728 9.5163
EFO-27 GDSC1; GDSC2; CTRP2; CTRP1 6.9894 9.8659 5.3109 4.9655
SNU-8 CTRP2 7.2495 8.6072 6.1093 1.3105
EFO-21 GDSC1; GDSC2; CTRP2 7.6711 11.3636 5.0755 4.8482
OVISE GDSC1; GDSC2; CTRP2 7.7701 10.8928 5.3687 3.5324
ONCO-DG-1 CTRP2 8.012 10.0981 5.8796 1.3423
OV56 GDSC1; GDSC2; CTRP2 8.0619 9.2846 6.2368 0.279
ES2 CTRP2 8.1767 13.7725 4.2621 7.3789
JHOS-2 GDSC1; GDSC2; CTRP2 8.2902 11.2418 5.5287 2.3015
Kuramochi GDSC1; GDSC2; CTRP2 8.4197 12.1664 5.1847 3.4303
MCAS CTRP2 8.7366 12.3969 5.2674 2.7776
OVSAHO CTRP2 8.92 10.764 6.0347 0.3591
SK-OV-3 GDSC1; GDSC2; CTRP2 8.9481 10.4438 6.1606 0.151
HEY A8 CTRP2 8.9959 10.7354 6.0751 0.2634
FU-OV-1 GDSC1; GDSC2; CTRP2 9.3672 18.0939 2.9987 10.4829
OVTOKO GDSC1; GDSC2; CTRP2 9.5903 11.226 6.1208 0.0937
COV644 CTRP2; CTRP1 9.6016 18.2845 3.0657 9.9121
SNU-840 CTRP2; CTRP1 10.6492 18.4295 3.6598 6.4817
OAW28 GDSC1; GDSC2; CTRP2 11.1064 19.1342 3.609 6.1657
⏷ Show the Full List of 48 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 8 Cell Line(s) in Pleura Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NCI-H2452 GDSC1; GDSC2; CTRP2 4.8659 11.0049 2.8488 19.5707
MPP 89 GDSC1; GDSC2; CTRP2 6.186 6.7727 6.1038 3.3418
NCI-H28 GDSC1; GDSC2; CTRP2 7.2167 10.9257 4.9596 6.0413
MSTO-211H GDSC1; GDSC2; CTRP2 7.6538 9.8564 5.7809 2.0769
ACC-MESO-1 CTRP2 8.6192 10.0042 6.1934 0.1788
IST-Mes1 GDSC1; GDSC2; CTRP2 9.0018 10.9533 5.9975 0.4017
NCI-H2052 GDSC2; CTRP2 9.582 11.1062 6.158 0.0663
JL-1 CTRP2 11.0784 19.1832 3.5707 6.3259
⏷ Show the Full List of 8 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Prostate Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NCI-H660 GDSC2 5.297 6.8989 2.7927 0.4717
PC-3 GDSC1; GDSC2 5.434 8.004 2.4188 1.786
LNCaP clone FGC GDSC1; GDSC2; CTRP2 6.3786 7.8103 5.8271 3.9782
PaCa-3 CTRP2; CTRP1 6.5815 7.2138 6.3054 1.546
DU145 GDSC1; GDSC2; CTRP2 6.6877 10.2784 4.863 7.3933
22Rv1 GDSC1; GDSC2; CTRP2 7.0284 13.2737 3.6437 11.7929
VCaP GDSC1; GDSC2; CTRP2 10.3372 18.8713 3.2656 8.2378
⏷ Show the Full List of 7 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Salivary Gland Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
A-253 GDSC1; GDSC2; CTRP2 6.0603 6.6941 5.9925 4.1228
YD-15 CTRP2 8.3333 9.3908 6.3031 0.0943
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Small Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuTu 80 GDSC1; GDSC2 4.1069 6.2194 2.4636 3.531
Cancer Drug Sensitivity Data Curated from 44 Cell Line(s) in Stomach Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HSC-39 GDSC1; GDSC2 2.8335 3.5205 2.724 5.499
SK-GT-2 GDSC1; GDSC2 3.5973 5.5964 2.4052 5.0512
HGC-27 GDSC1; GDSC2; CTRP2 3.674 5.6675 3.6078 19.991
AGS GDSC2; CTRP2; CTRP1 3.7649 4.5321 3.7647 19.1621
ECC10 GDSC1; GDSC2; CTRP2 3.8714 5.2138 3.8585 18.4958
MKN28 GDSC2 3.9505 8.4636 1.2543 11.2552
SNU-16 GDSC1; GDSC2; CTRP2 4.1615 7.2863 3.7356 18.0433
GCIY GDSC2 4.1724 6.934 2.1661 5.1812
SCH GDSC1; GDSC2 4.3171 5.7723 2.793 1.3356
TGBC11TKB GDSC1; GDSC2 4.3736 7.5579 2.0033 5.7336
RERF-GC-1B GDSC1; GDSC2 4.4508 9.4891 1.121 10.7947
SNU-216 CTRP2 4.6782 7.8603 4.0769 15.289
MKN1 GDSC1; GDSC2; CTRP2 5.0245 5.6653 5.0222 10.7856
RF-48 GDSC1; GDSC2 5.2716 7.1388 2.6911 0.8192
SNU-601 CTRP2 5.3779 7.8657 4.8083 10.557
OCUM-1 GDSC2 5.5084 8.5516 2.226 2.6041
TMK-1 GDSC1; GDSC2 5.6179 7.3289 2.762 0.3992
NCC-StC-K140 CTRP2 5.7838 7.3951 5.4304 7.0406
Hs 746.T GDSC1; GDSC2; CTRP2 6.0762 6.6008 6.0355 3.9194
KATO III GDSC1; GDSC2; CTRP2 6.184 6.9099 6.0507 3.5487
KE-39 CTRP2 6.5096 13.8751 2.9158 15.655
SNU-620 CTRP2 7.0289 10.6692 4.9424 6.4352
GSU CTRP2 7.153 7.894 6.3748 0.4482
SNU-1 GDSC1; GDSC2; CTRP2 7.4248 13.8403 3.6739 10.9583
23132/87 GDSC1; GDSC2; CTRP2 7.7909 13.5557 4.0911 8.664
MKN45 GDSC1; GDSC2; CTRP2 7.8957 8.9705 6.2862 0.2427
HuG1-N CTRP2 7.9757 13.4681 4.2679 7.6596
SH-10-TC CTRP2 8.0815 12.0506 5.0243 4.4758
GSS CTRP2 8.1105 11.1744 5.4528 2.7804
MKN7 GDSC1; GDSC2; CTRP2 8.2571 14.0047 4.2058 7.484
ECC12 GDSC2; CTRP2 8.4327 11.3171 5.5758 1.9913
Fu97 GDSC1; GDSC2; CTRP2 8.5047 10.0836 6.1193 0.3461
SNU-5 GDSC1; GDSC2; CTRP2 8.5129 9.9361 6.1771 0.2342
NUGC-3 GDSC1; GDSC2; CTRP2 8.569 10.1265 6.1295 0.3022
MKN74 CTRP2; CTRP1 8.6442 14.0021 4.4685 5.9061
NUGC-4 GDSC1; GDSC2; CTRP2 8.6618 10.7461 5.9314 0.7108
IM95 GDSC1; GDSC2; CTRP2 8.688 12.4294 5.2248 2.9819
LMSU CTRP2 8.705 10.7513 5.9487 0.6433
SNU-668 CTRP2 8.9884 10.1529 6.2733 0.042
NCI-N87 GDSC1; GDSC2; CTRP2 9.1533 16.2407 3.7412 8.0212
SNU-719 CTRP2 11.411 28.2265 -0.4791 18.1752
SNU-685 CTRP2 8.6158 12.6391 5.0866 3.5716
SNU-1077 CTRP2 9.5121 10.9836 6.175 0.0611
SNG-M GDSC1; GDSC2; CTRP2; CTRP1 10.8605 19.3195 3.38 7.2205
⏷ Show the Full List of 44 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 18 Cell Line(s) in Thyroid Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
IHH-4 GDSC1; GDSC2 3.6225 5.921 2.2636 5.876
HTC-C3 GDSC1; GDSC2 4.2941 8.2414 1.6178 8.2293
8505C GDSC1; GDSC2; CTRP2 4.406 6.1915 4.3086 15.2283
K5 GDSC1; GDSC2 4.8829 6.8222 2.6379 1.395
ASH-3 GDSC1; GDSC2 5.0149 6.5056 2.8243 0.5394
CAL-62 GDSC1; GDSC2; CTRP2 5.1106 5.8898 5.1013 10.2362
ML-1 [Human leukemia] GDSC1; GDSC2; CTRP2 5.1924 7.9064 4.5983 11.8729
WRO GDSC1; GDSC2 5.5242 7.3814 2.7054 0.6044
KMH-2 GDSC1; GDSC2 5.5306 7.2217 2.7669 0.426
SW579 CTRP2 5.9917 6.5087 5.9639 4.4359
TT2609-C02 GDSC1; GDSC2; CTRP2 6.9576 8.8437 5.7932 3.0112
8305C GDSC1; GDSC2; CTRP2 7.0857 9.3141 5.6567 3.3674
FTC-133 GDSC1; GDSC2; CTRP2 8.3468 9.641 6.2195 0.2118
FTC-238 CTRP2 8.4956 10.3212 6.0244 0.5655
BHT-101 GDSC1; GDSC2; CTRP2 8.5741 9.8256 6.2395 0.1258
CGTH-W-1 GDSC1; GDSC2; CTRP2 8.575 10.3238 6.0578 0.4485
B-CPAP GDSC1; GDSC2; CTRP2 8.8853 10.2219 6.2146 0.1004
TT GDSC1; GDSC2; CTRP2 10.6069 28.4954 -1.1809 20.9398
⏷ Show the Full List of 18 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 56 Cell Line(s) in Upper Aerodigestive Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HO-1-u-1 GDSC1; GDSC2 2.6863 5.7555 1.5419 13.2476
DOK GDSC1; GDSC2 3.5434 5.5054 2.4088 5.1686
Ca9-22 GDSC1; GDSC2 3.7339 6.5329 2.0455 6.9562
BICR 10 GDSC1; GDSC2 3.8032 8.1242 1.3092 11.3144
OSC-20 GDSC1; GDSC2 3.8271 6.6709 2.0476 6.7095
SCC-4 GDSC1; GDSC2; CTRP2 3.9478 4.9254 3.9458 17.9509
PCI-30 GDSC1; GDSC2 4.0488 6.5442 2.269 4.8254
HO-1-N-1 GDSC1; GDSC2 4.1619 6.6474 2.2964 4.4181
SAS GDSC1; GDSC2 4.243 6.3247 2.5011 3.0503
LB771-HNC GDSC1; GDSC2 4.2693 8.3217 1.5608 8.6296
SAT [Human HNSCC] GDSC2 4.4003 11.2296 0.2269 15.7954
KOSC-2 GDSC1; GDSC2 4.5975 7.0085 2.4019 2.9957
UPCI-SCC-090 GDSC1; GDSC2 4.6009 6.9733 2.4199 2.8913
CAL-33 GDSC1; GDSC2; CTRP2 4.6053 5.9958 4.5567 13.733
OSC-19 GDSC1; GDSC2 4.6719 7.9033 2.0348 4.9522
NCI-H3118 GDSC1; GDSC2 4.6781 7.3898 2.2763 3.5607
KON GDSC1; GDSC2 4.8013 6.8874 2.5688 1.8201
SKN-3 GDSC1; GDSC2 4.8516 8.4861 1.8761 5.5291
YD-8 CTRP2 4.9513 6.76 4.7638 11.9247
SCC-15 GDSC1; GDSC2 5.0046 10.6855 0.9306 10.6064
BB30-HNC GDSC2 5.0209 7.2772 2.5164 1.803
JHU-011 GDSC1; GDSC2 5.0577 6.9628 2.6643 1.1023
HSC-4 GDSC1; GDSC2; CTRP2 5.0855 5.523 5.0853 10.3728
PCI-04B GDSC1; GDSC2 5.1358 8.3585 2.1064 3.7473
PCI-38 GDSC1 5.1495 6.8965 1.7595 0.2797
BICR 31 GDSC2; CTRP2 5.3573 10.5247 3.5491 15.6641
BB49-HNC GDSC1; GDSC2 5.5277 16.0338 -1.3026 19.8336
PCI-15A GDSC1; GDSC2 5.5545 7.2586 2.7629 0.4256
BICR 78 GDSC1; GDSC2 5.5629 13.6228 -0.1016 14.6647
JHU-029 GDSC1; GDSC2 5.8367 9.1738 2.1307 2.6591
PE/CA-PJ15 GDSC1; GDSC2; CTRP2 5.9091 9.5761 4.528 10.4093
PCI-06A GDSC1; GDSC2 5.9313 7.7761 2.7214 0.3684
FaDu GDSC1; GDSC2; CTRP2 5.9928 6.4991 5.967 4.4214
HSC-2 GDSC1; GDSC2; CTRP2 6.0583 6.5543 6.0269 4.0056
PE/CA-PJ49 CTRP2 6.1066 6.5849 6.0726 3.6934
PE/CA-PJ41 (clone D2) CTRP2 6.19 18.9026 0.1323 25.2472
PE/CA-PJ34 (clone C12) CTRP2 6.6537 7.8367 6.0557 2.451
JHU-022 GDSC1; GDSC2 7.0849 20.8044 -2.5166 20.7606
BHY GDSC1; GDSC2; CTRP2 7.3736 11.4269 4.8299 6.318
BICR 6 CTRP2 7.7696 9.693 5.9238 1.4218
BICR 16 CTRP2 7.8873 12.5296 4.6618 6.2031
SCC-9 GDSC1; GDSC2; CTRP2; CTRP1 8.0179 11.3901 5.2948 3.4986
SNU-1076 CTRP2 8.2844 9.7899 6.1383 0.3982
SNU-46 CTRP2 8.3187 10.3687 5.9227 0.9541
BICR 56 CTRP2 8.3522 11.668 5.3723 2.8063
CAL-27 GDSC1; GDSC2; CTRP2 8.4674 10.0044 6.1337 0.3313
HSC-3 GDSC1; GDSC2; CTRP2 8.5239 9.809 6.2268 0.1533
SCC-25 GDSC1; GDSC2; CTRP2 8.5942 16.6867 3.1405 11.1072
BICR 22 GDSC1; GDSC2; CTRP2 8.6484 10.3062 6.0949 0.3406
SNU-899 CTRP2 8.7301 9.9071 6.2671 0.0718
YD-10B CTRP2 8.8354 10.0523 6.2547 0.0698
SNU-1214 CTRP2 8.9598 11.1484 5.9059 0.6185
SNU-1041 CTRP2 9.0485 10.94 6.0212 0.3404
BICR 18 CTRP2 9.2361 10.8547 6.1224 0.1432
Detroit 562 GDSC1; GDSC2; CTRP2 9.2565 16.3136 3.7745 7.7565
SNU-1066 CTRP2 9.5886 10.8952 6.2296 0.0279
⏷ Show the Full List of 56 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 24 Cell Line(s) in Urinary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CAL-29 GDSC1; GDSC2; CTRP2 3.6063 5.1141 3.5901 20.2711
U-BLC1 CTRP2 3.98 4.7709 3.9796 17.7311
TCCSUP GDSC1; GDSC2; CTRP2 4.3265 5.3279 4.3209 15.4425
SW780 GDSC1; GDSC2 4.4088 9.023 1.3186 9.7428
HT-1197 GDSC1; GDSC2; CTRP2 4.6507 13.0904 -0.504 16.4766
KMBC-2 CTRP2 4.7921 5.744 4.7802 12.3649
BFTC-905 GDSC1; GDSC2; CTRP2 4.8782 5.6289 4.8743 11.7647
253J CTRP2 4.9085 5.5451 4.9071 11.5549
T24 GDSC1; GDSC2; CTRP2 6.0461 6.7021 5.9747 4.2305
BC-3C CTRP2 6.2094 6.669 6.1626 3.056
JMSU-1 CTRP2 7.2908 10.7233 5.115 5.275
639V GDSC1; GDSC2; CTRP2 8.0208 11.0246 5.467 2.8326
RT-112 GDSC1; GDSC2; CTRP2 8.4319 10.1213 6.0742 0.4772
647V GDSC1; GDSC2; CTRP2 8.7283 13.9284 4.5577 5.4507
UM-UC-3 GDSC1; GDSC2; CTRP2 8.7384 12.9356 5.0247 3.6628
HT-1376 GDSC1; GDSC2; CTRP2 8.9691 10.5849 6.1187 0.203
J82 GDSC1; GDSC2; CTRP2 9.0295 11.3527 5.857 0.7011
VM-CUB-1 CTRP2 9.0953 13.6588 4.9074 3.7
RT-4 GDSC1; GDSC2; CTRP2 9.1576 10.6731 6.1568 0.1184
SCaBER CTRP2 9.2939 14.7521 4.5276 4.876
5637 GDSC1; GDSC2; CTRP2 9.3774 16.0826 3.9617 6.8938
SW1710 GDSC1; GDSC2; CTRP2 9.494 11.4199 6.0195 0.2216
UM-UC-1 CTRP2 9.8013 18.3114 3.185 9.2107
KU-19-19 GDSC1; GDSC2; CTRP2 12.8274 26.2565 1.3866 11.3688
⏷ Show the Full List of 24 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 39 Cell Line(s) in Urogenital System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NT2-D1 GDSC1; GDSC2 2.7898 10.3255 -0.6326 24.4974
TC-YIK GDSC1; GDSC2 3.1632 7.3123 1.193 13.8433
CAL-39 GDSC1; GDSC2 3.3348 6.8303 1.5784 10.9713
DSH1 GDSC1; GDSC2 3.5575 5.6437 2.351 5.4957
Ca Ski GDSC1; GDSC2 3.6657 9.2357 0.6464 15.5346
PWR-1E GDSC1; GDSC2 3.7572 5.6773 2.4844 4.1632
NCC-IT GDSC2 3.7664 6.7026 1.9862 7.2441
SW756 GDSC1; GDSC2 3.9309 6.3475 2.2817 5.0118
NEC8 GDSC1; GDSC2 3.9514 5.6852 2.6147 2.9443
SKG-IIIa GDSC1; GDSC2 4.1295 6.593 2.3007 4.46
PA-1 GDSC2 4.1767 8.3757 1.4672 9.4127
SiHa GDSC1; GDSC2 4.2249 6.448 2.4321 3.4858
DoTc2 4510 GDSC1; GDSC2 4.2746 6.1366 2.607 2.3926
C-33 A GDSC1; GDSC2 4.3077 11.2354 0.1537 16.4039
OVMIU GDSC1; GDSC2 4.3724 7.1476 2.1977 4.5781
SiSo GDSC1; GDSC2 4.3815 7.1139 2.2195 4.4316
HEC-1 GDSC1; GDSC2 4.4023 6.6697 2.4398 3.1151
PEO1 GDSC1; GDSC2 4.4442 8.6959 1.5031 8.5708
C-4-I GDSC1; GDSC2 4.46 8.1528 1.7766 6.9058
MS751 GDSC1; GDSC2 4.5583 10.085 0.9072 11.7551
KGN GDSC1; GDSC2 4.7564 11.6337 0.2925 14.5791
LB831-BLC GDSC1; GDSC2 4.82 8.075 2.0475 4.6058
JEG-3 GDSC1; GDSC2 4.8305 6.9343 2.564 1.8065
HT-3 GDSC1; GDSC2 5.0735 9.0926 1.733 5.9323
BPH-1 GDSC1; GDSC2 5.1218 12.9625 -0.0931 15.6163
SKN GDSC1; GDSC2 5.2089 11.9634 0.4548 12.6993
UWB1.289 GDSC1; GDSC2 5.2277 7.3144 2.6019 1.2019
HEY GDSC1; GDSC2 5.2847 8.8711 1.9621 4.2922
SW962 GDSC1; GDSC2 5.3623 8.0309 2.3718 2.0826
SW954 GDSC2 5.3646 7.2088 2.7041 0.7081
OVCA433 GDSC1; GDSC2 5.4534 7.3849 2.6745 0.7481
ME-180 GDSC1; GDSC2 5.4754 14.7763 -0.7248 17.6395
OMC-1 [Human cervical carcinoma] GDSC1; GDSC2 5.5315 7.3301 2.7275 0.5346
JAR GDSC1; GDSC2 5.5419 7.459 2.6835 0.6619
OV17R GDSC1; GDSC2 5.6818 7.5077 2.722 0.4736
OVCA420 GDSC1; GDSC2 5.8521 13.6876 0.066 13.2552
ACC-OV7 GDSC1; GDSC2 6.2324 15.5217 -0.5559 15.297
JHOS-3 GDSC1; GDSC2 6.3191 8.0132 2.7796 0.157
HeLa GDSC1; GDSC2; CTRP2 7.9135 8.7547 6.3716 0.0908
⏷ Show the Full List of 39 Cancer Drug Sensitivity Data of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Tamoxifen
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Eribulin. Breast cancer [2C60-2C6Y] [30]
Talazoparib DM1KS78 Moderate Decreased clearance of Tamoxifen due to the transporter inhibition by Talazoparib. Breast cancer [2C60-2C6Y] [31]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Lapatinib. Breast cancer [2C60-2C6Y] [30]
Tucatinib DMBESUA Moderate Decreased metabolism of Tamoxifen caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [32]
Alpelisib DMEXMYK Moderate Increased metabolism of Tamoxifen caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [33]
Bosutinib DMTI8YE Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Bosutinib. Breast cancer [2C60-2C6Y] [34]
⏷ Show the Full List of 6 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Tamoxifen (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Tamoxifen and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [35]
Nateglinide DMLK2QH Moderate Decreased metabolism of Tamoxifen caused by Nateglinide mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [36]
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Tamoxifen and Ivosidenib. Acute myeloid leukaemia [2A60] [37]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Midostaurin. Acute myeloid leukaemia [2A60] [30]
Idarubicin DMM0XGL Moderate Decreased clearance of Tamoxifen due to the transporter inhibition by Idarubicin. Acute myeloid leukaemia [2A60] [38]
Daunorubicin DMQUSBT Moderate Decreased clearance of Tamoxifen due to the transporter inhibition by Daunorubicin. Acute myeloid leukaemia [2A60] [38]
Arn-509 DMT81LZ Moderate Increased metabolism of Tamoxifen caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [39]
Gilteritinib DMTI0ZO Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Gilteritinib. Acute myeloid leukaemia [2A60] [40]
Oliceridine DM6MDCF Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Oliceridine. Acute pain [MG31] [30]
Rivastigmine DMG629M Moderate Increased risk of ventricular arrhythmias by the combination of Tamoxifen and Rivastigmine. Alzheimer disease [8A20] [30]
Donepezil DMIYG7Z Moderate Increased risk of ventricular arrhythmias by the combination of Tamoxifen and Donepezil. Alzheimer disease [8A20] [30]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Tamoxifen and Metronidazole. Amoebiasis [1A36] [35]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Tamoxifen and Ivabradine. Angina pectoris [BA40] [34]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Tamoxifen and Bepridil. Angina pectoris [BA40] [30]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Tamoxifen and Dronedarone. Angina pectoris [BA40] [30]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Tamoxifen and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [41]
Methylphenobarbital DMDSWAG Moderate Increased metabolism of Tamoxifen caused by Methylphenobarbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [39]
Posaconazole DMUL5EW Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Posaconazole. Aspergillosis [1F20] [30]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Levalbuterol. Asthma [CA23] [42]
Terbutaline DMD4381 Moderate Increased risk of ventricular arrhythmias by the combination of Tamoxifen and Terbutaline. Asthma [CA23] [43]
Pirbuterol DMI5678 Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Pirbuterol. Asthma [CA23] [43]
Salbutamol DMN9CWF Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Salbutamol. Asthma [CA23] [42]
Formoterol DMSOURV Moderate Increased risk of ventricular arrhythmias by the combination of Tamoxifen and Formoterol. Asthma [CA23] [43]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [34]
Desipramine DMT2FDC Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Desipramine. Attention deficit hyperactivity disorder [6A05] [30]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Ofloxacin. Bacterial infection [1A00-1C4Z] [44]
Dalfopristin DM4LTKV Major Decreased metabolism of Tamoxifen caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [45]
Clarithromycin DM4M1SG Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Clarithromycin. Bacterial infection [1A00-1C4Z] [30]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Tamoxifen and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [30]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Tamoxifen and Sparfloxacin. Bacterial infection [1A00-1C4Z] [44]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Gemifloxacin. Bacterial infection [1A00-1C4Z] [44]
Norfloxacin DMIZ6W2 Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Norfloxacin. Bacterial infection [1A00-1C4Z] [44]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Levofloxacin. Bacterial infection [1A00-1C4Z] [44]
Lomefloxacin DMVRH9C Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Lomefloxacin. Bacterial infection [1A00-1C4Z] [30]
Telithromycin DMZ4P3A Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Telithromycin. Bacterial infection [1A00-1C4Z] [30]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Tamoxifen and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [46]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [47]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Tamoxifen and Olodaterol. Chronic obstructive pulmonary disease [CA22] [43]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Tamoxifen and Vilanterol. Chronic obstructive pulmonary disease [CA22] [42]
Salmeterol DMIEU69 Moderate Increased risk of ventricular arrhythmias by the combination of Tamoxifen and Salmeterol. Chronic obstructive pulmonary disease [CA22] [43]
Indacaterol DMQJHR7 Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Indacaterol. Chronic obstructive pulmonary disease [CA22] [43]
Arformoterol DMYM974 Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Arformoterol. Chronic obstructive pulmonary disease [CA22] [43]
Phenylbutazone DMAYL0T Moderate Increased metabolism of Tamoxifen caused by Phenylbutazone mediated induction of CYP450 enzyme. Chronic pain [MG30] [39]
Fidaxomicin DMFP6MV Minor Decreased clearance of Tamoxifen due to the transporter inhibition by Fidaxomicin. Clostridium difficile enterocolitis [1A04] [35]
Isoproterenol DMK7MEY Moderate Increased risk of ventricular arrhythmias by the combination of Tamoxifen and Isoproterenol. Conduction disorder [BC63] [42]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Halothane. Corneal disease [9A76-9A78] [30]
Propofol DMB4OLE Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Propofol. Corneal disease [9A76-9A78] [48]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Probucol. Coronary atherosclerosis [BA80] [30]
Mifepristone DMGZQEF Major Increased risk of prolong QT interval by the combination of Tamoxifen and Mifepristone. Cushing syndrome [5A70] [30]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Tamoxifen and Pasireotide. Cushing syndrome [5A70] [30]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Osilodrostat. Cushing syndrome [5A70] [34]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Tamoxifen caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [49]
MK-8228 DMOB58Q Moderate Decreased metabolism of Tamoxifen caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [50]
Sertraline DM0FB1J Major Decreased metabolism of Tamoxifen caused by Sertraline mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [51]
Trimipramine DM1SC8M Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Trimipramine. Depression [6A70-6A7Z] [30]
Nefazodone DM4ZS8M Moderate Decreased metabolism of Tamoxifen caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [52]
Paroxetine DM5PVQE Major Decreased metabolism of Tamoxifen caused by Paroxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [51]
Clomipramine DMINRKW Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Clomipramine. Depression [6A70-6A7Z] [30]
Doxepin DMPI98T Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Doxepin. Depression [6A70-6A7Z] [30]
Maprotiline DMPWB7T Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Maprotiline. Depression [6A70-6A7Z] [30]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [30]
Deutetrabenazine DMUPFLI Moderate Additive CNS depression effects by the combination of Tamoxifen and Deutetrabenazine. Dystonic disorder [8A02] [53]
Ingrezza DMVPLNC Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Ingrezza. Dystonic disorder [8A02] [54]
Primidone DM0WX6I Moderate Increased metabolism of Tamoxifen caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [39]
Felbamate DM1V5ZS Moderate Increased metabolism of Tamoxifen caused by Felbamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [39]
Cenobamate DM8KLU9 Moderate Increased metabolism of Tamoxifen caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [39]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Tamoxifen caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [39]
Phenobarbital DMXZOCG Moderate Increased metabolism of Tamoxifen caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [39]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Tamoxifen and Cannabidiol. Epileptic encephalopathy [8A62] [34]
Diphenhydramine DMKQTBA Major Decreased metabolism of Tamoxifen caused by Diphenhydramine mediated inhibition of CYP450 enzyme. Episodic vestibular syndrome [AB31] [51]
Solifenacin DMG592Q Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Solifenacin. Functional bladder disorder [GC50] [30]
Mirabegron DMS1GYT Major Decreased metabolism of Tamoxifen caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [51]
Itraconazole DMCR1MV Moderate Decreased metabolism of Tamoxifen caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [55]
Pentamidine DMHZJCG Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Pentamidine. Fungal infection [1F29-1F2F] [30]
Terbinafine DMI6HUW Major Decreased metabolism of Tamoxifen caused by Terbinafine mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [51]
Ketoconazole DMPZI3Q Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Ketoconazole. Fungal infection [1F29-1F2F] [30]
Ripretinib DM958QB Moderate Decreased clearance of Tamoxifen due to the transporter inhibition by Ripretinib. Gastrointestinal stromal tumour [2B5B] [35]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Sunitinib. Gastrointestinal stromal tumour [2B5B] [30]
Sulfinpyrazone DMEV954 Moderate Increased metabolism of Tamoxifen caused by Sulfinpyrazone mediated induction of CYP450 enzyme. Gout [FA25] [39]
Rifampin DMA8J1G Moderate Increased metabolism of Tamoxifen caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [39]
Rifapentine DMCHV4I Moderate Increased metabolism of Tamoxifen caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [39]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Tamoxifen and Brentuximab vedotin. Hodgkin lymphoma [2B30] [56]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [57]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Tamoxifen caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [58]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Tamoxifen and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [59]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [30]
Darunavir DMN3GCH Moderate Decreased metabolism of Tamoxifen caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [60]
Maraviroc DMTL94F Moderate Decreased clearance of Tamoxifen due to the transporter inhibition by Maraviroc. Human immunodeficiency virus disease [1C60-1C62] [61]
Fenofibrate DMFKXDY Moderate Decreased metabolism of Tamoxifen caused by Fenofibrate mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [35]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Tamoxifen and Mipomersen. Hyper-lipoproteinaemia [5C80] [62]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Tamoxifen and Teriflunomide. Hyper-lipoproteinaemia [5C80] [30]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Tamoxifen and BMS-201038. Hyper-lipoproteinaemia [5C80] [63]
Cinacalcet DMCX0K3 Major Decreased metabolism of Tamoxifen caused by Cinacalcet mediated inhibition of CYP450 enzyme. Hyper-parathyroidism [5A51] [51]
Conivaptan DM1V329 Moderate Decreased metabolism of Tamoxifen caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [64]
Tolvaptan DMIWFRL Moderate Decreased clearance of Tamoxifen due to the transporter inhibition by Tolvaptan. Hypo-osmolality/hyponatraemia [5C72] [65]
Givosiran DM5PFIJ Major Decreased metabolism of Tamoxifen caused by Givosiran mediated inhibition of CYP450 enzyme. Inborn porphyrin/heme metabolism error [5C58] [51]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Tamoxifen caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [66]
Amobarbital DM0GQ8N Moderate Increased metabolism of Tamoxifen caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [39]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Tamoxifen and Polyethylene glycol. Irritable bowel syndrome [DD91] [34]
Naloxegol DML0B41 Minor Decreased clearance of Tamoxifen due to the transporter inhibition by Naloxegol. Large intestine motility disorder [DB32] [67]
Glycerol phenylbutyrate DMDGRQO Moderate Decreased metabolism of Tamoxifen caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. Liver disease [DB90-DB9Z] [34]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Tamoxifen and Crizotinib. Lung cancer [2C25] [68]
Brigatinib DM7W94S Moderate Increased metabolism of Tamoxifen caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [69]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Tamoxifen and Ceritinib. Lung cancer [2C25] [30]
PF-06463922 DMKM7EW Moderate Increased metabolism of Tamoxifen caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [39]
Dacomitinib DMOH8VY Major Decreased metabolism of Tamoxifen caused by Dacomitinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [51]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Tamoxifen and Osimertinib. Lung cancer [2C25] [70]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Tamoxifen and Selpercatinib. Lung cancer [2C25] [34]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Tamoxifen and Lumefantrine. Malaria [1F40-1F45] [35]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Tamoxifen and Hydroxychloroquine. Malaria [1F40-1F45] [71]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Primaquine. Malaria [1F40-1F45] [30]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [34]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Tamoxifen and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [72]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Tamoxifen and Idelalisib. Mature B-cell leukaemia [2A82] [73]
GDC-0199 DMH0QKA Major Decreased clearance of Tamoxifen due to the transporter inhibition by GDC-0199. Mature B-cell leukaemia [2A82] [35]
IPI-145 DMWA24P Moderate Decreased metabolism of Tamoxifen caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [74]
Arsenic trioxide DM61TA4 Major Increased risk of prolong QT interval by the combination of Tamoxifen and Arsenic trioxide. Mature B-cell lymphoma [2A85] [75]
Arry-162 DM1P6FR Moderate Decreased clearance of Tamoxifen due to the transporter inhibition by Arry-162. Melanoma [2C30] [35]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Tamoxifen and Vemurafenib. Melanoma [2C30] [30]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and LGX818. Melanoma [2C30] [76]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Tamoxifen caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [39]
Ubrogepant DM749I3 Moderate Decreased clearance of Tamoxifen due to the transporter inhibition by Ubrogepant. Migraine [8A80] [77]
Exjade DMHPRWG Moderate Decreased metabolism of Tamoxifen caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [78]
Carfilzomib DM48K0X Major Additive thrombogenic effects by the combination of Tamoxifen and Carfilzomib. Multiple myeloma [2A83] [35]
Panobinostat DM58WKG Major Decreased metabolism of Tamoxifen caused by Panobinostat mediated inhibition of CYP450 enzyme. Multiple myeloma [2A83] [51]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Tamoxifen and Siponimod. Multiple sclerosis [8A40] [35]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Tamoxifen and Fingolimod. Multiple sclerosis [8A40] [30]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Tamoxifen and Ozanimod. Multiple sclerosis [8A40] [79]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Romidepsin. Mycosis fungoides [2B01] [30]
Fedratinib DM4ZBK6 Major Decreased metabolism of Tamoxifen caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [51]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Tamoxifen and Nilotinib. Myeloproliferative neoplasm [2A20] [30]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Dasatinib. Myeloproliferative neoplasm [2A20] [80]
Prasugrel DM7MT6E Minor Decreased metabolism of Tamoxifen caused by Prasugrel mediated inhibition of CYP450 enzyme. Myocardial infarction [BA41-BA43] [34]
Modafinil DMYILBE Moderate Increased metabolism of Tamoxifen caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [39]
Promethazine DM6I5GR Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Promethazine. Nausea/vomiting [MD90] [30]
Rolapitant DM8XP26 Major Decreased metabolism of Tamoxifen caused by Rolapitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [51]
Granisetron DMIUW25 Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Granisetron. Nausea/vomiting [MD90] [30]
Dolasetron DMMG26Z Major Increased risk of prolong QT interval by the combination of Tamoxifen and Dolasetron. Nausea/vomiting [MD90] [30]
Ondansetron DMOTQ1I Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Ondansetron. Nausea/vomiting [MD90] [30]
Bupropion DM5PCS7 Major Decreased metabolism of Tamoxifen caused by Bupropion mediated inhibition of CYP450 enzyme. Nicotine use disorder [6C4A] [51]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Entrectinib. Non-small cell lung cancer [2C25] [35]
Lorcaserin DMG6OYJ Major Decreased metabolism of Tamoxifen caused by Lorcaserin mediated inhibition of CYP450 enzyme. Obesity [5B80-5B81] [51]
Dexfenfluramine DMJ7YDS Major Decreased metabolism of Tamoxifen caused by Dexfenfluramine mediated inhibition of CYP450 enzyme. Obesity [5B80-5B81] [51]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Tamoxifen and Levomethadyl Acetate. Opioid use disorder [6C43] [34]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Lofexidine. Opioid use disorder [6C43] [30]
Olaparib DM8QB1D Moderate Increased metabolism of Tamoxifen caused by Olaparib mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [35]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Rucaparib. Ovarian cancer [2C73] [30]
Buprenorphine DMPRI8G Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Buprenorphine. Pain [MG30-MG3Z] [30]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Triclabendazole. Parasitic worm infestation [1F90] [30]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Pimavanserin. Parkinsonism [8A00] [81]
Apomorphine DMX38HQ Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Apomorphine. Parkinsonism [8A00] [30]
Abametapir DM2RX0I Moderate Decreased metabolism of Tamoxifen caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [82]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Famotidine. Peptic ulcer [DA61] [35]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Tamoxifen and Macimorelin. Pituitary gland disorder [5A60-5A61] [83]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Tamoxifen and Lefamulin. Pneumonia [CA40] [84]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Tamoxifen caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [85]
Ritodrine DM4V6RL Moderate Increased risk of ventricular arrhythmias by the combination of Tamoxifen and Ritodrine. Preterm labour/delivery [JB00] [43]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Degarelix. Prostate cancer [2C82] [34]
ABIRATERONE DM8V75C Major Decreased metabolism of Tamoxifen caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [51]
Enzalutamide DMGL19D Moderate Increased metabolism of Tamoxifen caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [39]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Relugolix. Prostate cancer [2C82] [34]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Bicalutamide. Prostate cancer [2C82] [34]
Levomepromazine DMIKFEL Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Levomepromazine. Psychotic disorder [6A20-6A25] [30]
Riociguat DMXBLMP Moderate Decreased clearance of Tamoxifen due to the transporter inhibition by Riociguat. Pulmonary hypertension [BB01] [35]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Tamoxifen and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [86]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Tamoxifen and Gatifloxacin. Respiratory infection [CA07-CA4Z] [87]
Dexamethasone DMMWZET Moderate Increased metabolism of Tamoxifen caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [39]
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Quetiapine. Schizophrenia [6A20] [30]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Tamoxifen and Mesoridazine. Schizophrenia [6A20] [30]
Thioridazine DM35M8J Major Increased risk of prolong QT interval by the combination of Tamoxifen and Thioridazine. Schizophrenia [6A20] [30]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Tamoxifen and Iloperidone. Schizophrenia [6A20] [30]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Paliperidone. Schizophrenia [6A20] [30]
Perphenazine DMA4MRX Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Perphenazine. Schizophrenia [6A20] [30]
Trifluoperazine DMKBYWI Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Trifluoperazine. Schizophrenia [6A20] [30]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Tamoxifen and Amisulpride. Schizophrenia [6A20] [88]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Asenapine. Schizophrenia [6A20] [30]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Tamoxifen and Pimozide. Schizophrenia [6A20] [34]
Vardenafil DMTBGW8 Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Vardenafil. Sexual dysfunction [HA00-HA01] [30]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Tamoxifen caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [34]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Tamoxifen and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [34]
Armodafinil DMGB035 Moderate Increased metabolism of Tamoxifen caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [39]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Tamoxifen and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [30]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [34]
Doxorubicin DMVP5YE Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [30]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Tamoxifen and Naltrexone. Substance abuse [6C40] [89]
Fostamatinib DM6AUHV Moderate Decreased clearance of Tamoxifen due to the transporter inhibition by Fostamatinib. Thrombocytopenia [3B64] [90]
Lusutrombopag DMH6IKO Moderate Decreased clearance of Tamoxifen due to the transporter inhibition by Lusutrombopag. Thrombocytopenia [3B64] [91]
Apixaban DM89JLN Moderate Decreased metabolism of Tamoxifen caused by Apixaban mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [34]
Clopidogrel DMOL54H Minor Decreased metabolism of Tamoxifen caused by Clopidogrel mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [92]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Lenvatinib. Thyroid cancer [2D10] [30]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Tamoxifen and Cabozantinib. Thyroid cancer [2D10] [34]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Tamoxifen and Papaverine. Tonus and reflex abnormality [MB47] [93]
Tizanidine DMR2IQ4 Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Tizanidine. Tonus and reflex abnormality [MB47] [30]
Sirolimus DMGW1ID Moderate Increased plasma concentrations of Tamoxifen and Sirolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [86]
Tacrolimus DMZ7XNQ Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Tacrolimus. Transplant rejection [NE84] [30]
Elagolix DMB2C0E Moderate Increased metabolism of Tamoxifen caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [39]
Trimeprazine DMEMV9D Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [94]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Tamoxifen and Procainamide. Ventricular tachyarrhythmia [BC71] [30]
Propafenone DMPIBJK Major Decreased metabolism of Tamoxifen caused by Propafenone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [51]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Tamoxifen and Flecainide. Ventricular tachyarrhythmia [BC71] [30]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Tamoxifen and Amiodarone. Ventricular tachyarrhythmia [BC71] [30]
⏷ Show the Full List of 201 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Anethole E00440 637563 Flavoring agent
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Carboxymethylcellulose sodium E00621 Not Available Adsorbent; Binding agent; Disintegrant; Emulsifying agent; Suspending agent; Viscosity-controlling agent
Carmellose sodium E00625 Not Available Disintegrant
Ethanol E00023 702 Antimicrobial preservative; Penetration agent; Solvent
Glycerin E00026 753 Antimicrobial preservative; Emollient; Flavoring agent; Humectant; Lubricant; Plasticizing agent; Solvent; Suppository base; Tonicity agent; Viscosity-controlling agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Water E00035 962 Solvent
Sorbitan tristearate E00516 17800859 Dispersing agent; Emulsifying agent; Solubilizing agent; Surfactant; Suspending agent; Vaccine adjuvant
Pregelatinized starch E00674 Not Available Binding agent; Diluent; Disintegrant
⏷ Show the Full List of 18 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Tamoxifen 10 mg tablet 10 mg Oral Tablet Oral
Tamoxifen 20 mg tablet 20 mg Oral Tablet Oral
Tamoxifen Citrate eq 10mg base tablet eq 10mg base Tablet Oral
Tamoxifen Citrate eq 20mg base/10ml solution eq 20mg base/10ml Solution Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1016).
2 Tamoxifen FDA Label
3 FDA Approved Drug Products: Tamoxifen Oral Tablets
4 BDDCS applied to over 900 drugs
5 Lien EA, Anker G, Lonning PE, Solheim E, Ueland PM: Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide. Cancer Res. 1990 Sep 15;50(18):5851-7.
6 Fromson JM, Pearson S, Bramah S: The metabolism of tamoxifen (I.C.I. 46,474). I. In laboratory animals. Xenobiotica. 1973 Nov;3(11):693-709. doi: 10.3109/00498257309151594.
7 Brocks DR: Anticholinergic drugs used in Parkinson's disease: An overlooked class of drugs from a pharmacokinetic perspective. J Pharm Pharm Sci. 1999 May-Aug;2(2):39-46.
8 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
9 Lien EA, Solheim E, Lea OA, Lundgren S, Kvinnsland S, Ueland PM: Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. Cancer Res. 1989 Apr 15;49(8):2175-83.
10 Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer. J Natl Cancer Inst. 2010 Jul 7;102(13):942-9. doi: 10.1093/jnci/djq211. Epub 2010 Jun 16.
11 Modulators of vascular sex hormone receptors and their effects in estrogen-deficiency states associated with menopause. Recent Pat Cardiovasc Drug Discov. 2008 Nov;3(3):165-86.
12 Modulation of the ATPase and transport activities of broad-acting multidrug resistance factor ABCC10 (MRP7). Cancer Res. 2012 Dec 15;72(24):6457-67.
13 The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
14 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
15 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
16 Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
17 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
18 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
19 Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos. 2002 Aug;30(8):869-74.
20 Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
21 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
22 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
23 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
24 Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther. 2002 Jun;301(3):945-52.
25 Drug Interactions Flockhart Table
26 Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy. Future Oncol. 2014 Jan;10(1):107-22.
27 Tamoxifen-induced adduct formation and cell stress in human endometrial glands. Drug Metab Dispos. 2010 Jan;38(1):200-7.
28 Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases. Drug Metab Dispos. 2007 Nov;35(11):2006-14.
29 Polymorphism of estrogen metabolism genes and cataract. Med Hypotheses. 2004;63(3):494-7.
30 Canadian Pharmacists Association.
31 Product Information. Talzenna (talazoparib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
32 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
33 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
34 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
35 Cerner Multum, Inc. "Australian Product Information.".
36 Product Information. Starlix (nateglinide) Novartis Pharmaceuticals, East Hanover, NJ.
37 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
38 Multum Information Services, Inc. Expert Review Panel.
39 Biochem Pharmacol "Variable contribution of cytochromes P450 2D6, 2C9, and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes." Biochem Pharmacol 53 (1997): 171-8. [PMID: 9037249]
40 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
41 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
42 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
43 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
44 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
45 Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77. [PMID: 11103749]
46 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
47 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
48 Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
49 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
50 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
51 Amchin J, Ereshefsky L, Zarycranski W, Taylor K, Albano D, Klockowski PM "Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe." J Clin Pharmacol 41 (2001): 443-51. [PMID: 11304901]
52 Product Information. Serzone (nefazodone). Bristol-Myers Squibb, Princeton, NJ.
53 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
54 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
55 Auclair B, Berning SE, Huitt GA, Peloquin CP "Potential interaction between itraconazole and clarithromycin." Pharmacotherapy 19 (1999): 1439-44. [PMID: 10600094]
56 Product Information. VFEND (voriconazole). Pfizer U.S. Pharmaceuticals, New York, NY.
57 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
58 Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
59 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
60 Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
61 Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
62 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
63 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
64 Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN.
65 Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.
66 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
67 Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
68 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
69 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
70 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
71 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
72 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
73 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
74 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
75 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
76 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
77 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
78 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
79 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
80 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
81 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
82 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
83 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
84 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
85 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
86 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
87 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
88 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
89 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
90 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
91 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
92 Product Information. Plavix (clopidogrel). Bristol-Myers Squibb, Princeton, NJ.
93 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
94 Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]